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GENERAL INTRODUCTION 
The term Lower Urinary Tract Symptoms (LUTS) describes a wide range of condi-
tions regardless to the cause of these symptoms. Both symptoms of overactive 
bladder, such as urgency urinary incontinence or urgency-frequency, and urinary 
retention are included in the term LUTS.  
Urgency urinary incontinence has a prevalence of 5.6% in the Netherlands.1 For the 
Dutch population of about 16 million people this means that approximately 896,000 
persons are suffering from this ailment. Urinary incontinence and urgency-
frequency have a severe impact on the patients’ quality of life.2 The expenditure in 
the United States of America for urinary incontinence in female patients was 452.8 
million dollar in the year 2000. 
Patients with voiding dysfunctions, such as urinary retention with or without 
outflow obstruction, make up another group of patients with LUTS. There are no 
figures published on the occurrence of this condition, but this condition influences 
the quality of life of the patients and gives considerable associated costs as well, as 
these patients usually require frequent self-catheterization to empty their bladder.  
In conclusion, these two groups of LUTS mentioned above form an important 
problem in health care. Both the loss in quality of life as the high associated costs of  
disease justify the need for adequate treatment.  
 
In 1990 sacral neuromodulation (SNM) became available as a new treatment option 
in patients with urgency urinary incontinence, urgency-frequency and later non-
obstructive urinary retention. Sacral neuromodulation is modulation of the voiding  
reflex system by stimulating a sacral nerve with electrical current. Details on tech-
nique and mechanism of action are described further on in this thesis. 
 
In the last two decades sacral neuromodulation obtained a place in the list of ther-
apy options a physician has to offer to patients with LUTS, resistant to conservative 
therapy.  
AIMS OF THIS THESIS 
In this thesis long term results of SNM with regards to efficacy and safety, will be 
discussed. This thesis presents the results from both a multicenter as a single center 
study on long term results. It also contains research on an improved implant 
method and data on a new type of stimulator settings.  
Chapter 1 contains this introduction and outlines the aims of this thesis. In addition 
it contains an overview on the history and procedure of SNM. Chapter 2 gives an 
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overview of the neurophysiology of normal voiding. In addition, the current 
knowledge and hypotheses on the mechanism of action of SNM are discussed and a 
summary of the pathophysiology of the current indications of SNM is given. 
The data of the prospective multicenter study into the five-years results of sacral 
neuromodulation became available and are presented in Chapter 3. This study was 
carried out to measure long term efficacy and safety of SNM. It is an extension of 
the initial study by the manufacturer of the SNM equipment, Medtronic Inc, to gain 
FDA-approcal for SNM. 
In addition, a retrospective study was carried out into the results of sacral 
neuromodulation in the department of Urology in the Academisch Ziekenhuis in 
Maastricht. (Chapter 4). This study shows the influence of technical developments 
on the outcome of SNM and the resolution of adverse events encountered when 
applying sacral neuromodulation.  
One of these developments was the introduction of a minimal invasive method of 
electrode implant in 2003. Initial results with this method in our clinic are described 
in Chapter 5, as this method changes the SNM treatment algorithm.  
Chapter 6 is a study into the feasibility of interruption of neuromodulation. 
Intermittent neuromodulation might have a few advantages. It saves battery life of 
the implanted pulse generator and it might postpone or prevent the loss of efficacy 
in long term that some patients experience.  
In our outpatient clinic there was a number of female patients with an implanted 
neuromodulation system who spontaneously reported improvement in their sexual 
functioning. This led to the questions whether this improvement could be 
objectified and if this improvement was due to a physiological reaction on 
stimulation of the sacral root, leading to direct genital stimulation, or due to a 
psychological reaction because of an improved well-being through symptom 
resolution. The resulting study is described in Chapter 7.  
Chapters 8 and 9 conclude this thesis and contain an overview of future 
perspectives in SNM  
SACRAL NEUROMODULATION 
History 
The use of electricity for therapeutic goals was already described by Scribonius Lar-
gus in 46 AD. He described the use of electrically charged eels to treat pain in an-
cient Rome. In 1780 Galvani first observed the twitching of muscles in a frog’s leg 
when touched with an electrically charged object. In the following centuries, tech-
nical improvements and better understanding of electricity and biology led to the 
advent of Functional Electrical Stimulation (FES) as a therapeutic tool. 
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Already in the 20th century urinary retention was treated by direct electrical stimu-
lation of the detrusor or by transurethral stimulation.3 At the end of the sixth dec-
ade the application of FES became technically easier due to the development of the 
transistor. The interest for electrotherapy for lower urinary tract symptoms grew.4 
FES was used for restoring micturition in patients with retention and in patients 
with incontinence.5,6  
In 1974 Brindley published on the implantation of electrodes on the sacral nerve 
roots to stimulate bladder afferents.7 In 1976 this method of bladder stimulation 
was first applied in paraplegic patients to achieve bladder emptying. 
In implanted patients the ventral roots of S2, S3 and S4 are stimulated to achieve 
bladder contraction. A dorsal rhizotomy was carried out in these patients to abolish 
detrusor-sphincter dyssynergia and to decrease incontinence at higher bladder 
volumes. As the sphincter is stimulated simultaneously, voiding takes place due to 
interruption of the stimulation. The smooth detrusor muscle relaxes slowly, while 
the striated sphincter relaxes more rapidly, allowing for evacuation of urine 
between consecutive stimuli. This phenomenon is known as post stimulus voiding.  
 
The results of Brindley in paraplegic patients led to research into methods for selec-
tive stimulation of nerves to the bladder. In experiments using horseradish peroxi-
dase staining Thuroff discovered that the somatic innervation of the sphincter was 
represented in the spinal cord in the pudendal nucleus and the autonomic innerva-
tion of the bladder was controlled through a parasympathic nucleus.8 
Selective stimulation of these nuclei at spinal cord level is not possible, due to the 
localization of these nuclei in the spinal cord. In the eighties a group of researchers 
in Los Angeles did extensive research into the optimal site and method of bladder 
stimulation in spinalized dogs and later in patients with neurogenic bladder dys-
function.9 They found that selective stimulation of sacral roots was feasible and led 
to suppression of overactive bladder contractions. An explanation of this 
phenomenon was that the sphincter was stimulated by stimulation of efferent 
nerve roots and led to activation of the continence reflex.  
It was also hypothesized that stimulation of the sphincter complex could prevent 
incontinence by increasing outflow resistance. However, when research methods 
were more refined, it became clear that the reduction in incontinence was caused 
by inhibition of the detrusor muscle, instead of a direct effect on the sphincter.10  
This effect was confirmed by other authors who used different methods of electri-
cal stimulation, among others intravaginal stimulation and bulbocavernous stimula-
tion.11 
In the following period, Tanagho and Schmidt refined their stimulation techniques 
and developed the sacral neurostimulation method using foramen S3.12,13 In 1997 
SNM achieved FDA approval. The indication of this therapy was later on extended 
to patients with idiopathic urgency symptoms and urinary retention.14  
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Sacral Nerve Stimulation (SNS) therapy, as devised by Tanago and Schmidt, made 
use of a quadripolar lead connected to an Implantable Pulse Generator (IPG, collo-
quially known as ‘bladder pacemaker’). These were implanted in a surgical proce-
dure under general anesthesia. The lead was sutured over the sacral periost and 
subcutaneously tunneled with an extension wire to the IPG that was implanted in a 
subcutaneous pocket at the left or right lower abdominal quadrant. 
PROCEDURE OF SNM  
Temporary test procedure 
Patients that are candidates for SNM first undergo a test procedure, the so-called 
Peripheral Nerve Evaluation (PNE) During this test both acute and subchronic 
resonses to electrical stimulation are evaluated.  
After positioning the patient in a prone position, both third sacral foramina are 
identified, based on the superior illiac spines (at S2 level), the tip of the coccyx and 
the inferior illiac spine (at the level of S3).  
Both S3 foramina are located one centimetre laterally from the midline.15 After local 
anesthesia, taking care not to infiltrate the nerve, a needle is introduced. When the 
needle is in position, a small electric current is applied and slowly increased until 
the patient has a tingling, pulling or tapping sensation at the perineum or, 
respectively in females or males, the labia or scrotum.  
Expected motor responses at correct electrode placement are contraction of 
perianal muscles, the so-called ‘bellows response’ and plantar flexion of the great 
toe. When the responses are indicative of correct needle placement, a thin 
temporary lead is introduced through the needle and the needle is withdrawn, 
taking care to leave the lead in place. After careful dressing, an external stimulator 
is connected and the patient is sent home with instructions how to handle the 
stimulator and to avoid sudden flexion and extension of the back and carrying 
heavy objects. The electrode position is checked with an X-ray of the pelvis in two 
directions.  
After about week the electrode is removed. The patient has kept voiding diaries 
before and during stimulation. The voiding diary contains number of voids/day, 
volume/void, changes of incontinence pads/day, number of catheterizations, 
catheterized volume/catheterization. The diary data before and during stimulation 
are compared by computer software. A candidate is eligible for definitive electrode 
implant when there is at least 50% improvement in relevant voiding parameters 
during the test stimulation period.  
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Definitive implant  
Before the development of a minimal invasive implant method, implant took place 
in the operating room under general anesthesia.  
Nowadays definitive implants are performed under local anesthesia.16 The proce-
dure starts in the same manner as the PNE, but when the responses are satisfacto-
rily, a guide wire is advanced through the stimulation needle. After removing the 
needle a stylet is introduced. An quadripolar lead is placed through the stylet and 
its depth and is checked with fluoroscopy. Silicone tines allow for lead fixation once 
the stylet is removed.  
The lead is connected to an extension wire and tunneled subcutaneously to a 
created pocket about 3 centimetres below the illiac crest. An Implantable Pulse 
Generator (IPG) is connected to the extension wire and placed in the pocket. After 
wound closure and dressing, the IPG is programmed. Programming takes place with 
a telemetry device. As the lead has four poles, lead configuration is based on the 
best sensory response. Initial stimulation parameters are: continuous stimulation 
with a frequency of 10 Hz and pulsewith of 210 μsec. The amplitude is set to such a 
voltage that the patient feels the stimulation, but not in an unpleasant manner. 
Figure 1 is a schematic representation of an implanted SNM system.  
The patient is supplied with a Patient Programmer, that enables him/her to increase 
or decrease stimulation amplitude and to switch the stimulator off and on.  
After implant, regular follow-up visits are planned to check whether system settings 
are still optimal. Furthermore a troubleshooting service is available for patients with 
problems with their SNM system.  
 
 
Figure 1. Schematic representation
of an implanted SNM system. The
electrode is positioned in the left
third sacral foramen and connected
to an Implantable Pulse Generator
that is implanted in the upper left
buttock.  
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Chapter 2 
Backgrounds of normal voiding and 
indications for Sacral Neuromodulation 
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ANATOMY AND NEURAL CONTROL OF VOIDING 
The urinary tract consists of the kidneys, ureters, the bladder and the urethra with 
its sphincter system. In the male the prostate is considered a part of the urinary 
tract as well. For clinical reference the urinary tract is divided in two parts. The up-
per urinary tract consists of the kidneys with the abdominal part of the ureters. The 
lower urinary tract is formed by the part of the ureters that is below the level of the 
iliac vessels, the bladder and the urethra. The function of the urinary tract is to col-
lect and store urine and dispose of it at a convenient moment. 
 
 
Figure 1. A schematic diagram of the urinary tract. 
 
The bladder is a hollow muscular organ. Its average capacity for storing urine is 400 
– 500 ml. The inner surface of the bladder is covered with transitional epithelium, 
which consists of six layers of cells. In an empty bladder it is folded, but when the 
bladder is full, it becomes a smooth surface. Under this layer is the lamina propria, a 
layer of fibro-elastic connective tissue that supports distension of the bladder. 
External to the lamina propria is the detrusor muscle, a smooth muscle with fiber 
bundles running over the bladder. At the level of the bladder neck the detrusor 
forms three clearly distinguishable layers, at the top of the bladder the separate 
layers cannot be identified. The inner and outer layers are circularly oriented, while 
the middle layer has a longitudinal orientation. This arrangement of the detrusor 
muscle allows for efficient emptying of the bladder. 
In the storage phase unwanted urine outflow from the bladder is prevented by two 
sphincter systems. The internal sphincter lies at the bladder neck and consists of 
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smooth muscles. It works without conscious control and is controlled by sympa-
thetic innervation.1 
The external sphincter contains striated muscles and is under voluntary control. The 
axons that control the external sphincter are localized in the nucleus of Onuf, lo-
cated at S1 and S1 level in the anterior horn of the spinal cord. 
  
Voiding is controlled by three subsystems of the nervous system: the parasympa-
thetic, the orthosympathetic and the voluntary or somatic system. 
The parasympathetic nerves of the bladder and the sphincter originate in the sacral 
parasympathetic nucleus (SPN) at the second to fourth sacral segment and 
innervate the pelvic plexus. Their postganglionic fibers innervate the bladder, the 
internal sphincter and the urethra. The main neurotransmitter of the 
parasympathetic system is acetylcholine. The function of the parasympathetic 
innervation of the lower urinary tract is to initiate and propagate voiding.  
The orthosympathetic hypogastric nerves travel from the hypogastric plexus to the 
bladder neck and proximal urethra and innervate the muscle cells that form the 
internal sphincter. These nerves play an important part in the storage phase by 
relaxing the bladder, contracting the bladder neck and closure of the urethra and 
therefore facilitating urine storage. 
The voluntary innervation of the lower urinary tract carries information from the 
nucleus of Onuf. The Onuf nucleus lies in the ventral horn of the sacral spinal cord. 
The Aα motor neurons that originate from the Onuf nucleus towards the external 
urethral sphincter are part of the pudendal nerve. 
The afferent innervation of the bladder runs through the pudendal nerve, the pelvic 
nerve and the hypogastric nerve. It consists of myelinated Aδ-fibers that carry 
information from smooth muscle cells about bladder filling and unmyelinated C-
fibers that respond to bladder wall stretch, overdistention and noxious stimuli. 
Most C-fibers are silent and are only recruited when there is a painful stimulus.  
 
During the storage phase the bladder is filled with urine from the kidneys. Because 
of the elasticity of the bladder wall the pressure in the bladder rises almost unno-
ticeably. Assumed is that there is some uncoordinated activity in the smooth muscle 
cells of the bladder during filling, but it is not synchronous and does not lead to in-
creased pressure.  
Information about bladder fullness is carried from the smooth detrusor cells 
through Aδ-fibers to the spinal cord. In the posterior horn of the spinal cord the Aδ-
fibers activate interneurons that stimulate both the external sphincter through the 
pudendal nerve and the orthosymphatic system. 
During filling the sympathetic system controls the bladder, giving relaxation of the 
detrusor muscle and contraction of the internal sphincter. The parasympathetic 
system is inhibited. 
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The information of the Aδ-fibers is carried to the cerebrum through Lissauer’s tract 
up to the periaqueductal grey (PAG). The PAG is said to be involved in processing 
visceral afferent information and relaying it to other cerebral structures. The PAG is 
also considered as a part of the emotional system and plays a role in the processing 
of fear and anxiety.2 Therefore the PAG receives information from many other 
cerebral structures, including the frontal cortex  and from parts of the limbic sys-
tem.3 The PAG has a projection to the pontine micturition center (PMC), which is 
clinically referred to as the nucleus of Barrington.4,5,6  
 
The PMC consists of two separate regions. The L-region lies laterally in the PMC and 
is clinically referred to as ‘the continence center’. It projects to Onuf’s nucleus and 
facilitates contraction of the external sphincter. Stimulation of the L-region results 
in an increase of plevic floor EMG in cats, while a lesion in this area gives  
incontinence.7 
The M-region of the PMC lies medially in the pons and is colloquially known as the 
‘micturition center’. Electrical stimulation of the M-region of the PMC results in 
relaxation of the pelvic floor, followed by bladder contraction. Bilateral lesion of the 
M region results in urinary retention.8 
 
In essence, storing urine and voiding is executed by a series of bulbospinal reflex 
arcs, controlled by cerebral structures. The filling sensations of the bladder are car-
ried through the Aδ-fibers to the periaqueductal gray and relayed to the Barrington 
nucleus in the pons. In the storage phase of the micturition cycle the Onuf nucleus 
is stimulated by the L-region in the Barrington nucleus. The external sphincter is 
contracted and the detrusor is relaxed, allowing for storage of urine. 
 
Micturition usually begins voluntarily in healthy adult subjects, when time and place 
are acceptable for voiding. Although we know that voiding is started by voluntarily 
switching on the micturition reflex, it is not known which structure is responsible 
for switching. As the Barrington nucleus controls both continence and voiding in 
respectively the L-region and M-region, it would be logical to assume that theBar-
ringon nucleus regulates initiation of voiding. However, fiber tracing studies in cats 
show that in the pons are no interconnections between L- region and M-region.9 
Therefore, other cerebral structures must be responsible for the initiation of the 
voiding phase. 
Research with functional neuroradiology techniques as PET, fRMI or SPECT has im-
plicated many different cerebral structures in the start of the voiding phase, such as 
the prefrontal cortex, insula, anterior cingulate gyrus and cerebellum.10,11 
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Stimulation of the M-area of the PMC gives a sharp decrease of the urethral pres-
sure and relaxation of the pelvic floor, followed after a few seconds by contraction 
of the bladder. The sympathetic and voluntary spinal guarding reflexes that are re-
sponsible for continence are inhibited by the M-area. Voiding is sustained by a posi-
tive-feedback mechanism. Contraction of the detrusor muscle increases bladder 
wall stress. The Aδ-fibers increase their firing rate to the PMC, thereby increasing 
parasymphatic neuronal command to the detrusor. Another positive-feedback 
mechanism is that when urine passes the urethra, a reflex arc through the PMC 
induces bladder contraction. 
 
Voiding stops when the bladder is empty or contains a minimal amount of urine. 
The pressure in the bladder decreases and the reflexes that prolong the micturition 
switch off. 
MECHANISM OF ACTION OF SNM 
The exact way how SNM works in urinary symptoms is not clear. 
An initially suggested hypothesis was that neurostimulation on the S3 level ampli-
fied the continence reflex by stimulation of the pelvic nerve, running to the external 
sphincter.12 The contraction of perianal muscles, observed in acute stimulation of 
the S3 nerve root, was proposed as support for this theory.  
This hypothesis was disproved by Fowler et al, who found increased latencies with 
electromyography of the anal sphincter on stimulation of the S3 root, compared to 
stimulation of the pudendal nerve. These findings suggest that SNM acts through a 
polysynaptic reflex, but this study gave no distinction between a spinal or a su-
praspinal reflex .13  
In 2002, Schurch et al performed neuromodulation in patients with complete spinal 
cord injury.14 Through latency measurements the involvement of afferent pathways 
and spinal reflexes were confirmed. But as the SNM did not improve voiding in 
these patients with complete spinal cord injury, it was suggested that there are also 
supraspinal mechanisms involved in the action of SNM.  
In 2002 Braun at al described their results of electroencephalography in 10 patients 
with SNM.15 Four patients had neurogenic LUTS, 6 patients had idiopathic LUTS. 
They found a cortical potential complex at the postcentral gyrus in all patients, 
regardless if patients felt the simulation or not. The postcentral gyrus is the primary 
somatosensory cortex, so the occurrence of a potential when using SNM would only 
be logical in patients who feel the stimulation.  
In addition, Positron Emission Tomography (PET) studies have been performed in 
patients with urinary retention due to the Fowler Syndrome and compared with 
healthy control subjects.16 The 8 included patients with Fowler syndrome did not 
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show activity in the brain stem on bladder fullness, while the control subjects did. 
With an active SNM system there was activity in the brainstem in the patients and 
decrease of activity in the cingulate cortex, suggesting a cerebral contribution of 
SNM in patient with Fowlers’ syndrome.  
A study by the same research group with fMRI in patients with Fowler’s syndrome 
showed a different response in the periaqueductal gray on bladder filling when the 
SNM system is on.17 With a near empty bladder the PAG is not active in healthy pa-
tients. In patients with Fowler’s syndrome the PAG is active even when there is a 
little bladder filling. With SNM the activation of the PAG seems to normalize. The 
authors hypothesize that SNM blocks inhibition of afferent information from the 
bladder.  
In 2006 PET scanning was also performed in 20 patients with SNM for overactive 
bladder symptoms.18 The researchers found decreases in activation in the cingulate 
gyrus, in the thalamus and in the ventromedial frontal cortex. In acutely stimulated 
patients, activation was found in the postcentral gyrus, the insula and the 
ventromedial frontal cortex. Therefore they confirmed the results of Braun et al and 
indicated a similar mechanism in OAB as Dasgupta et al found in Fowler’s 
syndrome. 
 
Furthermore, in animal experiments with a neurogenic bladder model Shaker et al 
found inhibition of reflex contractions of the bladder with neuromodulation, to-
gether with changes in neuropeptides levels that suggest a mechanism involving a 
decrease in activation of the C-afferent nerve fibers.19 Normally, the C-afferent fi-
bers are silent. The increased expression of neuropeptides point to increased acti-
vation in spinal cord injury. It is, however, not clear whether these results are valid 
as well for idiopathic OAB and retention.  
 
In conclusion, based on the current information on the working mechanism of SNM, 
SNM might act mostly on the processing of sensory information from the bladder. 
There are indications that, at least in urgency-related symptoms, SNM has an influ-
ence on pathological transmission of afferent information from the bladder through 
the C-fibers, based on the results of Shaker et al. Furthermore, both in OAB and in 
retention there are indications that the processing of afferent information in the 
PAG and in the cingulate cortex is normalized with SNM.  
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INDICATIONS FOR SNM 
Symptoms of idiopathic overactive bladder 
Overactive bladder (OAB) is defined by the Incontinence Society (ICS) in 2002 as 
urgency, with or without urge incontinence, and usually with frequency and noc-
turia.20 The term OAB is a description of a symptom complex without information 
on the cause of the symptoms. The most characteristic symptom in this complex is 
urgency. The ICS definition of urgency is: “a sudden compelling desire to pass urine 
that is difficult to defer.” Urgency is considered the driving force behind the other 
symptoms that make out the ICS definition of OAB.21 OAB, with or without urinary 
incontinence, has a severe impact on quality of life, as patients with ‘OAB wet’ (OAB 
with incontinence) usually become dependent on sanitary pad use and patients 
with ‘OAB dry’ (OAB without incontinence) tend to plan their activities based on the 
vicinity of a toilet.  
Research into the causes of OAB is still ongoing. There are several contributing 
factors. There is strong evidence for a disbalance in voiding reflexes due to changes 
in the afferent innervation from the bladder. This hypothesis is among others based 
on the efficacy of intravesical administration of capsaicin or resiniferatoxin for 
symptoms of overactive bladder. Capsaicin is assumed to desensitize the C-afferent 
fibers running from the bladder.22,23,24 Recently, a relation is found between auto-
nomic dysfunction and OAB, suggesting a dysbalance in the voiding reflex.25  
Other research is focused on the properties and signal transduction between the 
myocytes that form the detrusor. Brading showed in 1997 that detrusor myocytes 
change their properties after denervation.26  
Recent neuroimaging studies also imply a cerebral mechanism in the pathogenesis 
of OAB symptoms, but more research is needed.27 
The diagnostic work-up of OAB is mainly aimed towards exclusion of possible 
known causes of OAB, such as neurological disease or infravesical obstruction. The 
value of cystometry for diagnosing idiopathic OAB is still under debate, as only 50-
80% of patients with OAB has evidence of an overactive detrusor on urodynamic 
investigation.28,29 It has its value, however, in excluding other causes of LUTS.  
The treatment algorithm in OAB starts with lifestyle counseling, such as decrease of 
fluid/caffeine intake and weight loss. This can be supplemented by pelvic floor 
training of pelvic floor myofeedback. A pharmacological option is the use of 
antimuscarinic medication. These drugs antagonize the acetylcholine receptor and 
there are several preparations that act more or less specifically on the receptors on 
the bladder wall.  
However, in a considerable proportion of patients relief of their OAB symptoms is 
not satisfactorily or the antimuscarinic drugs are not well tolerated because of their 
side-effects.30 These side-effects include: a dry mouth, dizziness or visual distur-
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bances. Estimated discontinuation rates of antimuscarinic drugs for OAB are 42% 
after four months and 72% after one year.31  
 
Second line therapy of OAB consists of botulin toxin application in the bladder or 
functional electrical stimulation.  
Botulin neurotoxin (BTX) is a neurotoxin, produced by the bacteria Clostridium 
botulinum. The protein acts on the terminal ends of axons and prevents the release 
of neurotransmitter. It has a preference for inhibiting Acetylcholine release and is 
therefore used as a local muscle relaxant. Medical uses for BTX include: reduction 
of muscle spasm or dystonia or treatment of excessive sweating. Its cosmetic use as 
treatment for facial wrinkles is also widely known. 
In urology, BTX is injected intravesically in the detrusor. BTX has been used in pa-
tients with neurogenic overactive bladder.32 Since 2005 it is applied in patients with 
idiopathic overactive bladder as well.33,34 Depending on study methodology the ef-
fectiveness of intravesical BTX ranges between 40 – 80%.35,36 Side-effects of intrave-
sical BTX are: urinary retention requiring periodic intermittent catherization, urinary 
tract infections or extravesical effects of the BTX. The effects of BTX wear off, 
therefore patients need repeated injection procedures with an interval of 4-9 
months.  
The use of BTX is not FDA-approved yet, due to the lack of data on long term 
effects.  
The other second line treatment is neuromodulation by electrostimulation.  
A site for neuromodulation is the posterior tibial nerve.37 Percutaneous Tibial Nerve 
stimulation has as an advantage over SNM that it is less invasive, but patients need 
repeated visits to the outpatient clinic to maintain efficacy.38 
In 2000 a multicentre trail on sacral neuromodulation in 51 patients with OAB 
symtoms showed significant symptom relief compared to a control group. After 
turnig the stimulator off the symtoms recurred, but after turning the stimulator on, 
the symptoms improved until up to 24 months.39 Further long term results make up 
a part of this thesis.  
Before the introduction of functional electrical stimulation and BTX the only 
therapeutic options for severe OAB symptoms that did not respond to lifestyle 
advise or drugs were invasive surgical procedures, such as bladder augmentation or 
urinary deviation procedures.  
Non-obstructive urinary retention 
Urinary retention is the loss of ability to urinate. The most likely cause of urinary 
retention is infravesical obstruction by an enlarged prostrate due to benign 
prostatic hyperplasia in males or urethral stenosis.  
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Functional causes of urinary retention are decreased or absent tonus of the detru-
sor muscle or hypertonia of the sphincter in pelvic floor dysfunction.  
An example of urinary retention in pelvic floor dysfunction is the Fowler syndrome, 
consisting of urinary retention with abnormal electromyographic activity of the ex-
ternal urethral sphincter and polycystic ovaries.40 The voiding dysfunction in this 
syndrome tends to react favourably on SNM.41 
Idiopathic urinary retention can occur after surgical procedures, especially after 
pelvic bowel surgery or surgery for spinal disc herniation.42 In many patients, how-
ever, a cause for the retention can not be found.  
Patients with functional urinary retention rely on clean intermittent catheterization 
(CIC) for emptying their bladder. Having to catheterize several times per day is an 
inconvenience. Little is known in the literature on the occurrence of urinary tract 
infections in patients who catheterize because of idiopathic urinary retention as 
most research on this matter is carried out on children or in patients with retention 
on a neurological basis.   
In 2001 a randomized trail of SNM in patients with idiopathic urinary retention was 
published.43 The researchers found that 69% of the 37 patients in the SNM group 
were able to void completely without catheterization and in patients who kept 
catheterizing significant reduction of volume per catheterization was found.  
Neurogenic bladder dysfunction  
The symptomatology of neurogenic bladder dysfunction depends on the neurologi-
cal localization of the lesion. 
The most important distinction is the central (upper motor neuron) or peripheral 
(lower motor neuron) localization of the lesion.  
Central lesions occur in cerebro or in the spinal cord, while the peripheral nerve 
system consists of the nerves that run from the spinal cord, including the cauda 
equina, to the bladder and sphincter complex. The localization of the lesion 
depends for a part on the neurological disease.  
Peripheral lesions give a detrusor hypotonia, that can be combined with an 
hypotonic sphincter. The clinical picture is either urinary retention or overflow 
incontinence. Central lesions give different clinical signs, depending on the 
localization of the lesions. Hyperreflexia of the detrusor, with or without detrusor-
sphincter dissynergia, is seen in spinal cord lesions at T12 or above. In the acute 
stage, the bladder is flaccid due to the spinal shock phase, lasting up to several 
months. Below T12 the spinal nerves branch out to their target organs. Therefore, a 
lesion below T12 is a lower motor neuron lesion and gives detrusor hypotonia.  
 
When SNM was introduced, neurogenic voiding symtoms formed a contra-
indication for SNM, as it was believed that an intact supraspinal reflex arc is re-
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quired for succesful SNM.44,45 Furthermore, many neurological conditions are pro-
gressive and therefore an initially favourable effect of SNM can wear off as the neu-
rologic disease progresses.  
A multicenter long term SNM study in nine patients with neurogenic OAB due to 
spinal cord injury all showed clinical improvement.46 But another study on tempo-
rary SNM in three patients with complete spinal cord lesions showed anal responses 
on EMG, but no results on voiding complaints.47 A reason for the discrepancy in 
these two studies might be that the completeness of the spinal cord lesion was not 
mentioned in the multicenter study.  
Chaabane et al published long term results of SNM in a group of patients with neu-
rogenic OAB or urinary retention.48 Of the 62 patients tested with a temporary im-
plant, 37 had a definitive SNM implant. 27 Patients had complete improvement 
after a mean follow-up of 4.3 ± 3,7 year.  
In a study on SNM in patients with OAB or retention after incomplete spinal cord 
injury, 9 of 13 patients with neurogenic retention achieved at least 50% improve-
ment in voiding parameters, in the OAB group 7 of 9 patients had improvement.49 
The spinal cord lesions were classified as AIS C of D, implying that the patients kept 
sensibility and at least some muscle activity below their lesion level, and therefore 
possibly at least partially intact voiding pathways. SNM may be a promising therapy 
in patients with neurogenic bladder dysfunction, but its success depends on careful 
selection of potential candidates.  
Fecal incontinence and constipation 
From the onset of SNM there were anecdotal stories of patients who had defeca-
tion complaints, beside their lower urinary tract symptoms and reported improve-
ment of these symptoms as well.  
In 1995 SNM was successfully applied in patients with idiopathic fecal inconti-
nence.50 The exact mechanism of action of SNM in fecal complaints is unclear, but 
in a study on perception of rectal sensation the stimulation seems to alter the rectal 
sensibility.51  
In a multicenter study in 2004 on SNM in 37 patients with fecal incontinence, mean 
number of incontinence episodes per week dropped from 16.4 to 2.0 at 24 months. 
Subjectively, the ability to postpone defecation improved as well.52 Later on, the 
indication of SNM was expanded to patients with constipation as well. In 2010 a 
multicenter study was published, analyzing the results of 62 patients. 45 patients 
achieved at least 50% symptom reduction during the PNE. At follow-up an average 
increase of defecation episodes was seen from 2.3 to 6.6 episodes in 39 patients.53 
Toileting time decreased with almost 50% from on average 105. minutes to 5.7 
minutes. These results led to an increased utilization of SNM in fecal symptoms.  
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Pelvic pain  
There are several chronic pelvic pain syndromes described in the literature.  
Interstitial cystitis (IC) is a condition characterized by bladder pain, usually relieved 
by voiding, and frequency, nocturia and pelvic pain. It is a very bothersome 
condition and it predominantly occurs in women. IC has a multifactorial patho-
genesis. Damage to the bladder wall, increased expression of cytokines and changes 
in neural plasticity are some of the mechanisms that are implicated.54,55  
As SNM was incidentally applied in patients with refractory complaints of pelvic 
pain, several researchers started to apply SNM in patients with IC.  
In 2001 Maher et al applied temporary SNM in fifteen patients with interstitial 
cystitis, refractory to other treatment modalities, and found significant increases in 
volume per void (90 to 143 ml). Number of voids were decreased from 11 to 6 times 
per day.56 
The effect of SNM on interstitial cystitis was confirmed by Comiter who performed 
definitive SNM implants in 17 patients.57 After an average follow-up of 14 months 
the average frequency at daytime decreased from 17.1 to 8.7 and nocturia de-
creased from 4.5 to 1.1. Mean volume per void increased from 111 to 264 ml.  
(p < 0.01). Pain scores (from 0 to 10) decreased from 5.8 to 1.6 points. 
The long term effect of SNM on interstitial cystitis is not clear. Until now there are 
no results of prospective long-term studies available.  
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ABSTRACT 
Purpose: This 5-year, prospective, multicenter trial evaluated the long-term safety 
and efficacy of sacral neuromodulation in patients with refractory urge inconti-
nence (UI), urgency-frequency (UF), and retention.  
Material and Methods: A total of 17 centers worldwide enrolled 163 patients (87% 
female). Following test stimulation, 11 patients declined implantation, and 152 
were implanted using InterStim® (Medtronic Inc, Minneapolis). Of those treated 
with implantation, 96 patients (63.2%) had urge incontinence, 25 (16.4%) had ur-
gency frequency, and 31 (20.4%) had retention. Voiding diaries were collected an-
nually for 5 years. Clinical success was defined as 50% or greater improvement from 
baseline in primary voiding diary variable(s).  
Results: Data for all implanted cases were reported.  
For patients with urge incontinence, the mean number of leaking episodes per day 
decreased from 9.6 + 6.0 to 3.9 ± 4.0. For patients with urgency-frequency, mean 
voids per day decreased from 19.3 ± 7.0 to 14.8 ± 7.6 and mean voided volume per 
void increased from 92.3 ± 52.8 to 165.2 ± 147.7 ml. For patients with retention, the 
mean volume per catheterization decreased from 379.9 ± 183.8 to 109.2 + 184.3 ml 
and the mean number of catheterization decreased from 5.3 ± 2.8 to 1.9 ± 2.8. All 
changes were statistically significant (p< 0.0001). No life-threatening or irreversible 
adverse events occurred. In 102 patients 297 device-related or therapy-related ad-
verse events were observed. At 5 years after implantation, 68.0% of patients with 
urge incontinence, 56.0% with urgency frequency and 71.0% with retention pa-
tients had successful outcomes. 
Conclusions: This long-term study demonstrates that InterStim therapy is safe and 
effective for restoring voiding in appropriately selected cases refractory to other 
forms of treatment. 
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INTRODUCTION 
During the last decade, sacral neuromodulation (SNM), often referred to as sacral 
nerve stimulation (SNM) or InterStim therapy, has proven to be an effective treat-
ment modality for voiding dysfunctions that are refractory to conservative treat-
ment, particularly urge urinary incontinence (UI), urgency-frequency (UF) and idio-
pathic nonobstructive retention.1-11 In Europe, this therapy has also shown excellent 
clinical outcomes in treating fecal incontinence and idiopathic constipation, but 
these indications are not approved in the United States. Many patients treated with 
SNM experience an immediate clinical benefit that is sustained over long-term fol-
low-up. Several authors have published their results with SNM, reporting on various 
follow-up periods and success rates. As new techniques, devices, and components 
emerge, analysis of long-term data, particularly those gathered from the original 
patient groups enrolled in FDA-approved protocol studies, is important to advance 
our knowledge of SNM.  
This study, one of the earliest and largest prospective, multicenter clinical trials of 
SNM therapy, has concluded after 5 years of follow-up. We report here the long-
term results. 
MATERIAL AND METHODS 
This Post-Approval Study (PAS) was a prospective, nonrandomized, multicenter, 
follow-up study initiated after U.S. Food and Drug Administration (FDA) approval of 
InterStim Therapy. Most of the enrolled patients (129) were already implanted with 
the InterStim system for the treatment of UI, UF, and nonobstructive urinary reten-
tion as part of the multicenter, randomized controlled study (MDT-103) and were 
consecutively crossed-over to the long-term follow-up study. All 17 Ethical Commit-
tees approved the long-term PAS protocol and each patient signed an informed 
consent form before study participation. Six of the 23 centers participating in the 
original randomized study1,2 (MDT-103) declined to participate in the PAS and those 
patients were excluded from further follow-up. No significant differences between 
patients from the declined and the participating centers could be identified.  
Patient selection and evaluation 
The PAS study enrolled a total of 163 patients. Demographic data of 1 patient was 
not available. The mean age was 44.7 years ± 11.2 years (17.5 – 78.9) with 21 males 
(13%) and 141 females (87%). By indication 103 patients (63.6%) had UI, 28 (17.3%) 
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had UF, and 31 (19.1%) suffered from complete or incomplete urinary retention. A 
total of 129 patients crossed-over from the MDT-103 study and 34 were enrolled 
under the new PAS protocol. Of these 34 patients, 23 were implanted with the In-
terStim system and 11 declined a permanent implant despite a positive response to 
trial stimulation. The five-year results for all 152 patients are reported.  
The PAS study used a patient follow-up protocol similar to the original MDT-103 
study.12,13 Compared to the MDT-103 study, the PAS required annual follow-up vis-
its, and used more advanced devices (test stimulation leads, implantable neu-
rostimulators) and new techniques (neurostimulator implant in the buttock). The 
majority of patients had the INS implanted in the abdomen (121) and only 31 
patients who were enrolled later on, had the INS implanted in the buttock. The 
criteria for rating clinical success based on patients’ voiding diaries and the methods 
for reporting and analyzing AE’s remained unchanged. The required data at the 
annual follow-up visits for all implanted patients who underwent implantation 
included a voiding diary completed for a minimum of 3 days, and simple Uroflow 
and quality-of-life questionnaires. The questionnaires used were the Short Form-36 
(SF-36) and the Beck Depression Index (BDI). Detailed data were also collected on 
any concomitant treatment for the urological condition and on any therapy or 
patient related complication.  
 
The voiding dysfunction indications (UI, UF, and retention) were represented by 
unique primary voiding diary variables on which therapy outcome was measured. 
For UI patients, these voiding diary variables included: number of leaking episodes 
daily, number of heavy leaking episodes daily, and  number of pads used daily. 
For patients with UF, primary voiding diary variables included: number of voids 
daily, volume voided per void and degree of urgency experienced before void.  
For patients with retention, primary voiding diary variables included: catheterized 
volume per catheterization and number of catheterizations daily. InterStim Therapy 
was considered successful if a minimum of 50% improvement occurred in any of 
primary voiding diary variables compared with the baseline. Safety data were 
reported for all cases. Descriptive summaries were provided for device or therapy 
related AE’s and also those requiring surgical intervention.  
Patient Disposition 
In this long term follow-up study patients were followed up for 5 years. Due to the 
long follow-up period, some scheduled visits were missed and not all patients pro-
vided a voiding diary at each follow-up visit. Table 1 provides a breakdown of the 
follow-up elements by patient group (numbers of visits, diaries and explants) at 
each follow-up period. A total of 138 patients completed 1-year follow-up and 121 
patients completed the 1-year voiding diary. At 5 years a total of 105 patients com-
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pleted follow-up and 87 completed the voiding diary. There were 47 patients who 
did not have 5-year data, and 16 of them had the system explanted and withdrew 
due to lack of efficacy or complications. The last follow-up visit with diary data oc-
curred on average at 49.3 months 15.9 (range 11 to 60) following implantation for 
the 145 patients with at least 1 follow-up diary past 12 months. 
Statistical Analysis 
For each of the primary voiding diary parameters relevant for measurement of UI, 
UF, and retention, statistical comparisons were made between baseline and post 
implant using a repeated measure analysis. A clinical success rate (percentage of 
patients with 50% or more improvement in the voiding diary variable) at each visit 
was calculated for each primary voiding diary variable.  
 
Patients who exited the study due to an adverse event or lack of efficacy were con-
sidered unsuccessful and were assumed to return to their baseline. 
For patients who missed a study visit or failed to provide a voiding diary at a follow-
up visit for other reasons, the last observation carried forward was used to impute 
missing data. A sensitivity analysis based on all implanted cases with valid follow-up 
and diary data were also performed to assess the robustness of the results.  
 
Table 1. Breakdown of follow-up elements by post implant visit.  
Indication Follow-up 
(Number) 
Month 
12  
Month 
24  
Month 
36  
Month  
48  
Month  
60  
Visits 87 79 72 69 65 
Diaries 71 65 61 57 54 
Urge 
Incontinence 
(Baseline,  
N=96) 
Explants  due to complication  or 
lack of efficacy (cumulative) 
 1  2  3  4  8 
Visits 27 26 28 28 27 
Diaries 27 24 26 19 22 
Retention  
(Baseline, 
N=31) Explants  due to complication  or 
lack of efficacy (cumulative) 
 0  0  0  1  1 
Visits 24 19 16 16 13 
Diaries 23 19 14 16 11 
Urgency /  
Frequency (Base-
line, 
N=25) 
Explants  due to complication  or 
lack of efficacy (cumulative) 
 0  2  5  6  7 
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RESULTS 
Efficacy for Urge incontinence 
The average number of leaking episodes per day at baseline for the patients with 
(UI) was 9.6 + 6.0. This decreased to 4.7 + 4.9 at 1-year follow-up and the reduction 
was maintained throughout follow-up with an average of 3.9 ± 4.0 at 5 years after 
implantation. (Part A of figure 1)  
 
The number of heavy leaks per day decreased from 2.6 + 3.3 at baseline to 1.2 + 2.7 
leaks at 1-year follow-up, and to 0.8 + 1.7 at 5 years after implantation.  
Patients with urge incontinence also showed a decrease in the number of pads used 
per day, from more than 5 at baseline to 1.8 at at 5 years after implantation. A 
clinical success rate of 58% was observed in number of leaks per day, 68% in 
number of heavy leaks per day and 61% in number of pads used per day at 5-year 
follow-up (Table 2).  
 
Table 2. Clinical success rates for 5 years 
Clinical success rates for 5 years after implantation by indication and visit 
 1-Year 2-Year 3-Year 4-Year 5-Year 
% UI (No/Total No):       
Leaking episodes per day 51.0% (49/96) 60.4% (58/96) 59.4% (57/96) 58.3% (56/96) 58.3% (56/96) 
Heavy leaking episodes per day 50.0% (40/80) 60.8% (48/79) 66.7% (52/78) 68.0% (53/78) 68.0% (53/78) 
Pads per day 51.1% (45/88) 59.6% (53/89) 53.9% (48/89) 57.5% (50/87) 60.9% (53/87) 
% UF (No/Total No):      
Voids/day 40.0% (10/25) 48.0% (12/25) 52.0% (13/25) 48.0% (12/25) 40.0% (10/25) 
Vol/void 60.0% (15/25) 68.0% (17/25) 64.0% (16/25) 56.0% (14/25) 56.0% (14/25) 
Degree of urgency 68.0% (17/25) 72.0% (18/25) 68.0% (17/25) 60.0% (15/25) 56.0% (14/25) 
% Retention (No/Total No):      
Catheters/day 67.7% (21/31) 64.5% (20/31) 67.7% (21/31) 67.7% (21/31) 58.1% (18/31) 
Vol/Catheter 67.7% (21/31) 77.4% (24/31) 77.4% (24/31) 71.0% (22/31) 71.0% (21/31) 
Denominator may vary over visits because of missing data  
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Figure 1. Average voiding diary parameters during 5 years after implant. A, pa-
tients with UI. B, patients with UF. C, patients with retention. Missing values were
imputed using last observation carried forward. Except for degree of urgency,
voiding parameter changes were statistically significant (p< 0.0001) from repeated
measure analysis.  
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Efficacy for Urgency-Frequency 
The average number of voids per day decreased from 19.3 ± 7.0 at baseline to 13.0 
± 7.9 at 1-year follow-up. This reduction was maintained throughout the long-term 
follow-up period with a slight increase to 14.8 ± 7.6 at 5 years after implantation 
(Part B of Figure 1). The average voided volume increased from 92.3 ± 52.8 ml at 
baseline to 169.9 ± 118.2 ml 1 year after implantation and effectiveness was main-
tained throughout the long-term follow-up period with average of 165.2 ± 147.7 at 
5 years after implantation. Patient with urgency/frequency patients reported a de-
crease in degree of urgency per day from 2.3 ± 0.6 at baseline to 1.9 ± 0.8 at one-
year follow-up and 2.1 ± 0.7 at 5-year follow-up. A clinical success rate of 40% was 
observed in number of voids per day and 56% in degree of urgency per day at 5 
years after implantation for patients with UF, and 56% experienced a 50% or more 
increase in average volume voided per void.  
Of the patients with a successful clinical outcome after 1 year implant 71% 
remained successful at 5 year follow-up.  
Efficacy for Urinary Retention 
The average number of catheterizations per day decreased from 5.3 + 2.8 at base-
line to 1.9 + 2.8, and 58% clinical efficacy was observed 5 after implantation. The 
average catheterized volume per catheterization decreased from 379.9 ± 183.8 ml 
at baseline to 109.2 + 184.3 ml and clinical success rate of 71% was observed 5 
years after implantation (Part C of Figure 1). 
 
Of those patients with an unsuccessful therapy outcome the therapy failure period 
ranged over 6-60 months post-implantation, with a mean failure period of 24 
months for all indications. To assess the robustness of reported results, sensitivity 
analysis was performed based on all evaluable patients with valid visits and diary 
data. Consistent results were obtained and, thus, not presented.  
The quality of life scores (Short Form-36 and Beck Depression Inventory) showed 
some improvement, but this was not statistically significant.  
Interpretation of these data is limited because of the generic nature of the selected 
questionnaires which were the only methods available at the time the study was 
designed.  
Safety 
The safety data were reported based on all implanted cases. There were 102 (67%) 
patients who had at least 1 device or therapy related adverse event. A total of 221 
AEs were recorded and most (96%) were resolved by the time the data was ana-
lyzed. A total of 110 adverse events required surgery in 60 patients. There were 92 
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patients analyzed who underwent implantation and did not have adverse events 
requiring surgical intervention. Overall, the system was explanted from 16 patients 
due to adverse event or lack of efficacy. 
 
Of the adverse events in 102 patients, 31 were device-related (24 patients, 15.8%), 
and 240 were therapy-related (97 patients, 63.8%) (Table 3). 
 
Among the 240 therapy-related events, the most frequently reported event was 
new pain or undesirable change in stimulation, which occurred 60 times in 41 pa-
tients (27.0% of all patients). Pain at the percutaneous nerve evaluation (PNE) or 
the implant site related to the implantable neurostimulator (INS) was the second 
most commonly reported event, occurring 40 times in 30 patients (19.7% of all pa-
tients). 
 Of the device-related adverse events, the most frequently reported were sus-
pected device problems (5.3%) and suspected lead migration (3.3%) (Table 3). 
Throughout the 5-year follow-up period, surgical intervention was required to 
resolve adverse events in 60 patients (110 events). 
Device exchange, which included replacement of the lead, the extension, or the INS, 
was the most common intervention, resulting from 52 adverse events in 36 patients 
(23.7%). The types of surgical interventions performed are shown in Table 4, 
including the percentage of patients who experienced an adverse event requiring 
those interventions. These figures include a group of patients who had an INS 
exchange because of battery depletion. A total of 60 (39.5%) patients experienced 
adverse event requiring device exchange. Of the 152 patients who were implanted 
and analyzed, 92 (60.5 %) did not have an adverse event requiring surgical 
intervention. 
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Table 3. Device or therapy related adverse events 
Adverse Event Device Related Therapy Related 
  No. of Pt. With 
AEs (% ) 
No. Cumula-
tive AEs 
No. of Pt. With 
AEs (% ) 
No. Cumula-
tive AEs 
New pain/undesirable change in  
stimulation 
2 (1.3)  2 41 (27.0)  58 
Pain at PNE or implant site – INS 1 (0.7)  1 29 (19.1)  39 
Suspected device problem 8 (5.3) 11 8 (5.3)   8 
Suspected lead migration 5 (3.3)  5 8 (5.3)   9 
Infection-PNE or implant site 0  0 12 (7.9)  14 
Sensation of electric shock 2 (1.3)  2 10 (6.6)  12 
Pain at PNE or implant site – Lead 0  0 12 (7.9)  13 
Undesirable change in voiding function 0  0 11 (7.2)  12 
Technical problems during PNE/implant 0  0 8 (5.3)   8 
Other 7 (4.6) 10 44 (29.0)  67 
Total 24 (15.8) 31 97 (63.8) 240 
 
Table 4. Device or therapy related adverse events requiring surgical intervention 
Device or therapy related adverse events requiring surgical intervention  
Surgical Intervention No patients with AEs (%) No cumulative AEs  
Device exchange 36 (23.7)  52 
Reposition of the IPG 12 (7.9)  16 
Reposition Lead and IPG 10 (6.6)  14 
Reposition Lead 10 (6.6)  12 
Permanent Explant 9 (5.9)  10 
Temporary Explant 2 (1.3)   2 
Other Surgical Intervention 2 (1.3)   2 
Bilateral Implant 1 (0.7)   1 
Surgical Wound Care 1 (0.7)   1 
Any Adverse Event 60 (39.5) 110 
DISCUSSION 
This long-term, prospective, multicenter, FDA-regulated study represents the most 
comprehensive follow-up study of sacral neuromodulation therapy with the largest 
patient population to be analyzed or published to date.  
The efficacy data confirm the sustained clinical benefit of sacral neuromodulation 
that has been shown in various patient populations reported in recent years.2,9,10,14 
A drawback of such a long-term trial is that they cannot assess new therapeutic 
advancements that occur after the study begins, which may potentially affect pa-
tient selection, procedure techniques, devices used, and overall patient outcomes. 
F I V E - Y E A R  R E S U L T S  O F  S A C R A L  N E U R O M O D U L A T I O N  T H E R A P Y  
 41 
Another disadvantage of the study is the missing data due to patients not attending 
at scheduled visits or becoming lost to follow up.  
Therefore, clinical implication from this study should be interpreted with caution 
although a sensitivity analysis was performed based on all evaluable data. 
Nonetheless, this study demonstrates that approximately 70% of the treated 
patients continued to experience therapeutic benefit after 5 years of the treatment. 
The approximately 30% of the patients who did not benefit from the treatment 
between 6 and 24 months follow-up is consistent with previously published 
literature.10  
 
Many possible explanations exist for treatment failure, including potential placebo 
effect of trial stimulation, insufficient test stimulation sensitivity before implanta-
tion and inadequate patient selection (e.g., severe disease state at the time of the 
study enrollment, presence of specific mental conditions, and previous medico-
social history). For instance, Weil et al, reporting on their long-term results in 36 
patients, found a striking correlation between secondary loss of therapeutic effect 
and the presence of a pre-existing psychiatric disorder in the medical history.9 
However, the effect of psychiatric disorders on the efficacy of neuromodulation has 
not been established. 
 
An important finding in this study is the high correlation between the 1- and 5-year 
success rates for treated patients. There were 84% patients with UI, 71% with UF, 
and 78% with urinary retention who were successfully treated at 1-year follow-up 
continued to have a successful outcome at 5 years after implantation.  
 
SNM has proved to be a safe therapy that does not preclude any other treatment 
options. The mid-term safety profile of SNM was established in the original MDT-
103 study with 219 implanted cases.12 No reports of any life-threatening or irre-
versible adverse events have been made in this or any previous studies of neuro-
modulation for urinary conditions. Of the 271 reported adverse events in this study, 
110 required surgery in 60 patients. The most common surgical interventions were 
device exchange or device repositioning, which are generally considered minor sur-
gical procedures. Pain at the PNE or implant site necessitating surgical intervention 
was the most common indication occurring in 11.8% of implanted patients 
throughout the course of the study. The second and third most common indications 
requiring surgical intervention were suspected lead migration and new pain or un-
desirable change in stimulation. As 12 of the 14 patients experiencing these adverse 
events had undergone implantation with an older Itrel-II® INS, which has been su-
perseded by the new InterStim INS, the mid-term and long-term number of device-
related surgical interventions is expected to decrease. INS exchange due to battery 
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depletion will continue to occur, on average, every 8 years. However, this is a minor 
intervention performed on an outpatient basis under local anesthesia.  
In 1999, the placement of the INS was changed from the abdomen to the buttock 
because buttock placement resulted in less pain and fewer infections postopera-
tively, which minimized the need for INS repositioning, and reduced operating 
time.15 Despite the lack of randomized controlled trials on the effect of buttock ver-
sus abdominal placement and its impact on the rate of surgical re-operation, clinical 
data seems to confirm convincingly a reduced rate of INS-related complaints. Analy-
sis of the occurrence of surgically corrected adverse events in both treatment 
groups in our study revealed that the re-operation rate due to pain at the INS site 
decreased in cases of buttock placement. The difference was not statistically signifi-
cant due to the relatively small number of patients who were enrolled in the study 
with the buttock neurostimulator implant. 
 
At 1-year follow-up post implant, 19.9% of the patients had adverse event resulting 
in surgical intervention, which increased to 42.1% by 5-years of follow-up. Of 152 
implanted cases, 92 did not have an adverse event requiring surgical intervention. 
Although this is a relatively high number, we emphasize that this was the first study 
in which SNM therapy was offered to quite severely affected patients and with 
steep learning curve.  
It should also be noted that patients, who experienced the loss of therapeutic 
effect, often underwent revision surgery because it was believed at the time that 
new lead placement or switching to the contralateral side would restore benefit. 
Revision surgeries were performed and repeated on each patient when a technical 
problem occurred, the device had to be replaced, or when pain complaints 
indicated a problem. A later study demonstrated that loss of therapeutic effect of-
ten cannot be resolved with revision surgery.14 
 
Patient selection and the SNM operating technique involved a steep learning curve. 
Some of the devices and surgical techniques used early in the study have been re-
placed by major advancements within the last 3 years. For example, the technique 
has become minimally invasive with the use of percutaneous lead placement under 
local anesthesia that allows patient participation to help determine sensory re-
sponses. Reported adverse event rates from recent literature are between 11 and 
22% Specifically for surgical revision, the rates change from 7% to 18% with follow-
up from 7 to 24 months.16-18 This clearly demonstrates a reduction in the adverse 
event rates with the new technology (minimally invasive technique and the use of 
the tined lead and upper buttock INS placement) Much has been learned at each 
centre regarding the requirements for success, including the need for experienced 
personnel and appropriate hospital set-up for optimal therapy delivery. These im-
provements are now being practiced in all centres providing SNM therapy. 
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CONCLUSION 
This long-term study dramatically advanced overall knowledge of sacral neuro-
modulation therapy for urinary dysfunction. The results show that sacral neuro-
modulation safely and effectively provides long-term relief for appropriately se-
lected patients with refractory UI, UF, and urinary retention. SNM is a safe, reversi-
ble, minimally invasive method that may be an appropriate alternative to more in-
vasive techniques for well selected patients. Although much has been learned, 
methods can still be optimized. Further research is warranted to elicit the mecha-
nism of action, to improve patient selection and the sensitivity of percutaneous trial 
stimulation, and to avoid adverse events after implantation.  
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ABSTRACT 
Objective: To analyze the influence of technical improvements of Sacral Nerve 
Stimulation (SNS) on the incidence of surgical interventions and subjective long-
term results of SNS.  
Methods: Retrospective, transversal study analyzing records of implanted patients 
at our department of Urology. 
Results: Of 149 patients analyzed, 107 had overactive bladder symptoms and 42 
had urinary retention. Mean follow-up was 64.2 (sd = 38.5) months. In the whole 
group 194 adverse events occurred. 6 Patients had infection in their implanted sys-
tem, but none was explanted for infection. Most events could be solved by giving 
advice or by reprogramming the stimulator. 129 reoperations have been performed 
and 21 patients had their system explanted. Analysis of the data shows a striking 
difference in the incidence of reoperations, but small differences in subjective re-
sults in the groups of patients implanted before or after 1996, suggesting that a 
proactive approach towards adverse events is worthwhile. 
Conclusions: SNS gives lasting benefit in patients with refractory symptoms of over-
active bladder and non-obstructive urinary retention. The differences in outcomes 
and incidence of re-operation can be attributed to the learning curve and technical 
and surgical improvements in the application of SNS. 
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INTRODUCTION 
In 1994 neuromodulation by sacral nerve stimulation (SNS) became available as a 
new treatment option for patients with refractory urge incontinence, urgency-
frequency and nonobstructive urinary retention.1,2,3,4 The SNS procedure is rela-
tively non-mutilating compared to other surgical procedures. Therefore, it gained a 
place in the list of therapeutic options a physician can offer to patients with the 
above-mentioned symptoms. Sacral neuromodulation is placed between non-
invasive therapies such as anticholinergics or pelvic floor training and surgical pro-
cedures, such as bladder augmentation and urinary deviation. Initially patients were 
implanted according to the protocol of a multicenter study initiated by the manu-
facturer of the implanted equipment in order to achieve FDA approval (MDT-
103).5,6,7,8 From the early application of SNS until now continuous research is carried 
out to improve this therapy and to determine the exact mechanism of action. This 
research has yielded some technical improvements in SNS. In the period covering 
our study the design of the Implantable Pulse Generator (IPG) has been changed 
two times, lead design has changed and there have been advancements in surgical 
techniques. In our experience these advancements have contributed to decreased 
complications rates as well as increased success rates in our patients receiving SNS 
therapy.9,10,11 This study is set up to confirm this hypothesis. 
METHODS  
This is a transversal cohort study. The surgery logs of the department of Urology of 
the University Hospital Maastricht covering the period between 1990 and Decem-
ber 2003 have been scrutinized for patients who either received a new definitive 
neuromodulation system or had revision surgery. Patients were included if they had 
follow-up of longer than one year and if complete data were available. All patients 
were implanted according to the open procedure as proposed by Tanagho and 
Schmidt.12 Patients who were implanted through the percutaneous tined lead pro-
cedure were excluded,9 as well as patients receiving bilateral stimulation. All pa-
tients had shown successful on screening using the Percutaneous Nerve Evaluation 
(PNE) with a temporary lead or after a two-stage procedure.13 12 patients had their 
definitive implant through a 2-stage procedure.  
 
The first series of patients were implanted with the Itrell-I IPG, which was the first 
model used for SNS. Parameter change in this model was done in an open surgical 
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procedure. The Itrell-II was introduced in 1994 and allowed parameter modification 
by the physician using an external programmer.  
Patients, implanted with the Itrell-II could switch the IPG on and off and choose 
between two preprogrammed settings by using a magnet.  
Since 1999 the Interstim IPG is used. This latest model is supplied with a patient 
remote control for switching the device on and off and for changing amplitude 
within a preprogrammed range. In our opinion this decreases the outpatient visits 
as patients can handle amplitude related events by themselves.  
The first model of the implanted lead had separate fixation connectors, which had 
to be sutured onto the lead. In 1994 a new lead model was introduced which had 
fixation connectors integrated into the lead. 
From 2000 the IPG was implanted gluteally instead of abdominally, as this place-
ment gave less complications.10 
From the files of the implanted patients the following data were collected: 
• type of complaints; 
• date of implantation; 
• date and result of neuromodulation of last check-up; 
• number of adverse events and if adverse events had successfully been ad-
dressed; 
• date of reoperations for adverse events. 
 
Patient complaints were stratified on an ‘urge’ category and a ‘retention’ category. 
The urge category comprises patients suffering from urge incontinence or urgency-
frequency with or without pelvic pain complaints. The retention category consists of 
patients with non-obstructive retention, regardless of the cause of the complaints.  
The subjective results of the patients at their last visit were categorized as ‘good’ or 
as ‘insufficient’. The criteria for success were complete and lasting disappearance of 
symptoms or satisfactory symptoms for the patient. 
 
An insufficient result was noted when the patient was not satisfied, when symp-
toms recurred, in the case of an uncorrected adverse event or when the system was 
explanted. 
 
If at the last follow-up visit the stimulation parameters of the IPG were changed, 
the chart of the patient was analyzed a second time during the revision period of 
this manuscript and the result was noted. This is based on the fact that patients are 
instructed to report back if the symptoms do not improve. The patients are encour-
aged to contact the clinic when they suspect neuromodulation-related complaints.  
The number of adverse events the patient had in the period from implant until last 
follow-up was counted as well. An adverse event was noted when the patient had 
neuromodulation-related complaints, not solved by changing the stimulation 
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amplitude. Necessary outpatient reprogramming sessions of the stimulator for loss 
of sensation were only recorded as an adverse event if the loss of sensation was 
accompanied by loss of efficacy. Battery depletion of the IPG was recorded 
separately if the procedure was not combined with other neuromodulation related 
surgery. 
 
The data of the patients were analyzed using SPSS 11.5 for Windows (SPSS inc., 
USA).  
Analysis of contributing factors to the results was done using bivariate correlation 
analysis by Pearson’s Chi-square test. Further statistical analysis was performed 
using the Mann-Whitney test.  
RESULTS 
Between October 1990 and December 2002 190 patients were implanted. 15 pa-
tients were implanted less than a year ago, and therefore not analyzed. The data in 
the files of 26 patients was incomplete. In 17 of these files data on the implant was 
missing as these patients were implanted in another hospital and had reoperations 
in our department. In the remaining 9 files other data on adverse events or reop-
erations were missing. A total of 149 patients met the inclusion criteria and were 
analyzed. The group consisted of 27 male (18.1%) and 122 female patients (81.9%). 
Among these patients 129 (86.6%) had an idiopathic cause of their symptoms and 
20 (13.4%) patients had a neurologic cause of the urinary complaints.  
 
Table 1 shows the diagnosis and the results of these 20 patients. Indications for 
implant were overactive bladder symptoms in 107 (71.8%) and retention in 42 
(28.2%) patients.  
Mean age at implantation was 46.7 (sd = 10,0) years, range between 21 and 72 
years.  
 
Follow-up ranged between 12 and 154 months after implant, the mean follow-up 
period was 64.2 (sd = 38.5) months. 
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Table 1. The diagnosis of the 20 patients who have a neurologic cause of their urinary complaints and 
theirs results. ALS: Amyotrophic Lateral Sclerosis, IPD: Intevertebral Disk Prolaps, SCI: Spinal Cord Injury 
Diagnosis N of patients Result 
  Good Insufficient 
ALS 1 1 0 
Cauda Equina Syndrome 3 1 2 
Peripheral polyneuropathy 2 2 0 
Guillain Barre 1 1 0 
IDP 5 3 2 
SCI 1 1 0 
Multiple Sclerosis 1 1 0 
Paraplegia 1 0 1 
Spina Bifida 1 1 0 
Spondyolysis 1 1 0 
Whiplash 2 1 1 
Unknown neurologic  1 0 1 
Total 20 (100%) 13 (65%) 7 (35%) 
 
The mean follow-up for patients who were implanted for urgency symptoms was 
69.8 months (sd = 41.6) and for patients with urinary retention 70.5 months. 
(sd = 38.0). In the whole group 89 (59.7%) patients were scored as having a good 
result, 44 (29.5%) patients had insufficient results and 16 patients (10.7%) had a 
reprogramming session at their last visit.  
 
During the revision process of this manuscript the follow-up of these 16 patients 
after database closure showed that 11 (68.8%) had good results after a period of 
three to 6 months after their visit and 5 (31.3%) patients kept insufficient results 
after reprogramming.  
 
With these 16 patients included a total of 100 patients (67.1%) had a good result 
and 49 (32.9%) had insufficient results. 68 (63.6%) of the 107 patients with urgency 
had good results at the time of their last follow-up and 39 (36.4%) patients with 
urgency had insufficient results. 
 
In the retention group of 42 patients 32 (76.2%) patients had good results and 10 
patients (23.8%) had insufficient results.  
In the group of 149 patients with a total of 9,562 months of SNS experience 194 
adverse events occurred in 106 patients.  
 
There were no irreversible or severe adverse events. The most frequently occurring 
adverse events were changes in stimulation sensation, loss of efficacy and pain at 
the Implantable Pulse Generator (IPG) site.  
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Table 2. Description of adverse events in our follow-up.  
Adverse event    # 
Pain / undesirable change in stimulation  64 
Undesirable change in voiding function/ Loss of efficacy  42 
Pain at IPG implant site  41 
Adverse change in bowel function  15 
Suspected lead migration  10 
Suspected device problem (including lead breakage)   6 
Infection   6 
Technical problem   5 
Suspected neuropraxia   2 
Other   3 
Total  194 
The figures described in this table are numbers of adverse events. Some patients had more than one 
adverse event. Pain or undesirable stimulation was only recorded as an adverse event when changing 
the stimulator amplitude could not solve the problem. Suspected neuropraxia was seen in 2 patients 
who set their amplitudes very high and was in both patients successfully solved by switching the IPG off 
for 6 months. The events in the ‘Other’ category all were with one occurrence. 
 
Of all analyzed patients 48.3% had at least one reoperation due to an adverse 
event. 
A total of 129 reoperations have been performed in the total patient group to 
address adverse events, averaging 0.87 reoperations per patient.  
The most frequent surgical procedures were repositioning of the IPG because of 
pain, revision of the electrode because of suspected lead migration and reoperation 
for parameter change in patients implanted with the Itrell-I IPG. The 129 surgical 
procedures do not include replacement of the IPG for battery depletion. 
 
19 revisions for battery depletion took place in 18 patients. One patient who was 
implanted in 1992 has had two revisions for battery depletion. The mean life span 
of the replaced IPG’s in these patients was 73.7 months with a range between 28 to 
127 months. 
 
Chi-square correlation analysis between date of implantation, the sex of the pa-
tient, the type of complaints, follow-up time, the number of adverse events and 
whether the adverse events had been resolved at last follow-up and the result at 
last follow-up was performed.  
The analysis showed a significant correlation between result and adverse events 
being resolved: 0.830 (p = 0.000). Also the surgery per year ratio and the final  
results were correlated: 0.397 (p = 0.000). 
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However an inverse correlation was noted between result and the number of 
adverse events: 0.355 (p = 0.000). Patients without adverse events had the highest 
chance of a good result, but when patients had an adverse event, it was in most 
cases satisfactorily resolved.  
The Chi-square test did not show a significant difference between the results of 
patients with or without a neurologic cause for their complaints. 
Analysis of the data shows a clear decrease in the number of the adverse events 
and reoperations during the study period. Figure 1 shows the ratio of revisions and 
the ratio of adverse events in the patients implanted in each year divided by the 
number of implanted patients in that year.  
 
Table 3. The number of implants, adverse events, reoperations and the ratios of revisions/ implants and 
adverse events/implants for each year.  
Year # Implants # Revisions # Adverse events Revision ratio Events ratio 
1990  4 17 18 4.25 4.50 
1991 14 19 24 1.36 1.71 
1992  8 10 14 1.25 1.75 
1993  9  5 10 0.56 1.11 
1994 14 21 26 1.50 1.86 
1995 12 10 14 0.83 1.17 
1996 12 10 12 0.83 1.00 
1997 10 11 16 1.10 1.60 
1998 14  9 17 0.64 1.21 
1999 16  5 21 0.31 1.31 
2000 17  6 17 0.35 1.00 
2001 14  0  5 0.00 0.36 
2002  4  0  1 0.00 0.25 
2003  1  0  0 0.00 0.00 
 
L O N G  T E R M  R E S U L T S  
 53 
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
0
1
2
3
4
5
Ratio of AE's and revisions divided by number of implants.
Revision ratio AE ratio
Year
R
at
io
 
Figure 1. The ratio of revisions carried out in the patients implanted in each year divided by
the number of the implants in each year. Revisions for empty batteries are excluded.  
 
In the group of patients implanted before 1995 the mean number of reoperations 
was 1.56, while in the group of patients implanted after 1995 the mean decreased 
to 0.49 reoperations. This difference is statistically significant (p < 0.0001). 
The difference in the results between both groups changed as well: 60.7% of the 
patients implanted before 1995 had a good result while 65.9% of the patients 
implanted after 1995 had a good result. This difference is not statistically 
significant.  
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Figure 2. The amounts of patients with surgical revisions of their implanted system before / in 1995 and
after 1995. 
 
In 21 (14.1%) of the 149 patients the neuromodulation system had been removed.  
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The most common indication for explant was loss of efficacy (18 patients). The re-
maining three patients have been explanted due to uncorrectable side effects, one 
of these patients had an explant due to infection.  
Of the explanted patients 15 (71.4%) had urge symptoms, while 6 patients (28.6%) 
suffered from retention. The mean follow-up was 53.6 months (sd = 40.7), while the 
follow-up ranged between 12 and 145 months. Statistical analysis in the 21 
explanted patients shows a higher mean surgery/year ratio of 0.56 (sd = 0.09) than 
in the non-explanted group with a ratio of 0.12 (sd = 0.2) (p < 0.005). 
 
In 14 patients (66.7%) the operation in which the IPG was explanted was their only 
reoperation, in the remaining explanted patients the number of surgical sessions 
before the explant ranged between 1 and 11 sessions. 
DISCUSSION 
Sacral neuromodulation gives lasting and satisfactory relief in patients with refrac-
tory symptoms of overactive bladder and urinary retention.4,7,14,15,16 Because the 
study setup is retrospective and voiding diaries were not always found in the file, 
the outcome of the patients was based on patient and physician satisfaction. Usu-
ally patients are satisfied when they are without symptoms or have very few symp-
toms. These results, however, are not comparable to other studies because of the 
subjective measurement of the outcome. 
Some retrospective studies have been performed to identify predictive factors re-
garding the success of the Percutaneous Nerve Evaluation.17,18 So far no research 
has been done about predictive factors for the success of the definitive implant. In 
this study logistic regression analysis between result and date of implantation, sex 
of the patient, the type of complaints, follow-up time, the number of adverse 
events and whether the adverse events had been resolved at last follow-up has 
been carried out. However, none of these factors seemed to predict the outcome of 
neuromodulation. The therapy-dependent factors for a successful result that we 
identified were a low number of adverse events and surgical correction of an 
adverse event. There was no significant difference in the results between patients 
with complaints of neurogenic origin and idiopathic patients. The number of 
neurogenic patients (20 patients) was low in comparison with the non-neurogenic 
group (120 patients).  
 
Previous studies by Weil and by Everaerdt show that psychiatric factors play a role 
in the first-year results of SNS.4,19 Weil et al. described that patients with a previous 
history of psychiatric disorder are more prone to lose effect of their implanted neu-
romodulation system, while Everaert et al. demonstrated a greater chance of dif-
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ferent outcomes between the temporary test and definitive implant in patients di-
agnosed with psychiatric disease. To avoid bias by placebo effect in patients, we 
established the criterion of a minimum follow-up of one year.  
The rate of surgery for adverse events seems high, compared to other studies. In 
the literature the percentage of patients needing a reoperation is around 33%, 
while in our study we found a reoperation rate of 48.3%.4,5,7 
This suggests a considerable learning curve in patient selection. Throughout the 
years we select patients more strictly. In the early years potential candidates 
underwent up to five PNE’s when there was doubt if the patient reacted. Now 
patients get maximal two PNE’s before offering them a two-stage tined lead 
procedure or excluding them from neuromodulation. Furthermore improved tem-
porary lead design made the PNE more reliable.20  
Another reason for higher reoperation rates is that the used equipment was still 
under development in the early years of SNS. Figure 1 shows that the greatest 
decrease in both adverse events and reoperations is between 1991 and 1992. An 
important reason for the decrease in adverse events and surgical interventions is 
the experience that is accumulated, particularly in the first years of the application 
of sacral neuromodulation. In 1994 both the Itrell-II and a new definitive electrode 
became available. Figure 1 shows that in 1994 the adverse events ratio and the 
reoperation ratio rises. This suggests a learning curve after the introduction of the 
new techniques.  
The years thereafter the ratios drop, showing the benefits of the new techniques. 
The same phenomenon is seen in 1999 when the Interstim IPG is available and in 
2000 when the buttock placement is introduced. 
In 1997 Janknegt et al. tried to improve the testing procedure for neuromodulation 
by testing through the 2-stage procedure.13 The long-term efficacy of the 2-stage 
procedure has been determined by Scheepens et al.11 Recently the implant through 
the 2-stage procedure has been compared with the single-stage procedure in a ran-
domized trial and seems to give a higher chance of a good result.21 Since 2002 a 
new procedure has been developed for lead implant.22 This procedure allows for 
minimal invasive lead placement under local anesthesia. The procedure can take 
place on outpatient basis and the tined lead can easily be removed. Therefore two-
stage testing through the tined lead procedure has become a valuable addition to 
the PNE. Experience shows that the rate of patients with positive screening results 
increases by using the tined lead.9 his is probably because the tined lead is less sus-
ceptible to lead migration and the tined lead allows for longer screening periods. 
Since mid-2002 about 50 patients have been implanted with the tined lead 
procedure in our department. These patients are not included in this study. 
We suspect that use of patients’ sensory responses during the tined lead implant to 
guide lead placement gives less chance of failure of the definitive SNS system. 
Furthermore we expect a decrease in adverse events due to minimal invasive lead 
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implant. These hypotheses have yet to be confirmed in a trial, which is currently 
ongoing in our clinic.  
In 2000 buttock placement of the IPG has been investigated.10 The buttock place-
ment reduced average operating time from 2.5 to 1.5 hours because turning of the 
patient during surgery was not necessary and the flank incision was not performed. 
More importantly, postoperative pain, postoperative infections and the need for 
reoperations for IPG position-related pain were reduced. Despite the lack of a 
randomized trial the buttock placement has quickly become the standard method 
of IPG implant 
The occurrence of late failures remains still problematic in SNS. In this study 18 out 
of 149 patients have been explanted due to loss of efficacy. This group had more 
reoperations than the patients that were not explanted. No other predictors were 
found.  
The cause of this phenomenon is still unknown, although we suspect that 
neuroplasticity of the micturition center could play an important role. Currently a 
trial is ongoing, investigating the effect of bilateral stimulation in patients with 
therapy failure in our department. Still, more research is needed in this particular 
group of patients. 
CONCLUSION 
Sacral neuromodulation produces prolonged subjective benefit in a group of pa-
tients with highly therapy resistant lower urinary tract symptoms. The decrease in 
the number of adverse events and reoperations over the study period suggests a 
considerable learning curve in the selection, the implantation and follow-up of pa-
tients with neuromodulation. Other contributing factors are the development and 
implementation of new surgical techniques and the new technical developments as 
the external patient programmer and new implant hardware. 
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ABSTRACT 
Objective: Describing patient selection and results of implant for sacral neuromodu-
lation with the tined lead to median term follow-up. 
Patients and methods: 49 patients, 39 with refractory overactive bladder symp-
toms, 10 with urinary retention, were implanted with the tined lead under local 
anesthesia. The average test period was 12.4 days, (sd 5.8 days). Patients were im-
planted when they had at least 50% improvement in voiding diaries. Average fol-
low-up for implanted patients was 15.5 months (sd = 7.9 months). Change in void-
ing parameters was compared with the T-test.  
Results: 10 patients had a single stage implant, 39 had a two-stage implant. Of 39 
patients with 2-stage implant 31 (79.5%) were positive, 8 (20.5%) were not. 31 pa-
tients were included in follow-up. At last follow-up 28 (90.3%) patients had more 
than 50% improvement in diary parameters and 3 (9.7%) had not. In 21 patients 
with urgency symptoms the number of voids decreased from 11.7 ± 8.9 voids/day 
at baseline to 7.3 ± 3.4 voids (p = 0.1) Voided volume increased from 160.2 ± 70.7 
ml to 231.1 ± 119.5 ml (p = 0.001). Leakages/day decreased from 9.5 ± 8.7 to 3.3 ± 
2.2 (p=0.17). 
In 10 patients with retention the number of catheterisations decreased from 5.44 ± 
1.6 caths/day with a volume of 297.6 ± 76.8 ml to 1.2 ± 1.7 caths/day , volume was 
111.6 ± 158.1 ml. Mean number of voids increased from 3.7 ± 3.8 voids/day with a 
volume of 123.3 ± 141.7 ml to 4.2 ± 2.4 voids/day with a volume of 248.3 ± 146.0. 
There were no statistically significant differences in the parameters in the patients 
with retention.  
Seven patients had an adverse event. One incomplete electrode migration was seen 
and was treated conservatively.  
Conclusion: The new minimally invasive approach gives positive results on medium 
term. Two-stage testing with the tined lead seems to be more reliable than the clas-
sic PNE. The lead anchoring method seems sufficient for fixation of the electrode on 
median term. 
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INTRODUCTION 
Since its introduction about a decade ago sacral neuromodulation is applied in pa-
tients with refractory urge incontinence, urgency-frequency and non-obstructive 
urinary retention.1-5 Typically, potential candidates are tested with a temporary lead 
before the implantation of a definitive neuromodulation system is considered. 
Clinical experience with the test procedure for neuromodulation showed that the 
temporary electrode is prone to migration during the subchronic test phase. 
 
Due to this fact and due to the probability of bacterial infections in temporary elec-
trodes that are implanted for a long period of time, the duration of the subchronic 
test phase is limited to a maximum of approximately one week. Moreover, there is 
a certain group of implanted patients who experience inconsistencies between the 
results of the test period and the results of the definitive implant.  
In 2003 Spinelli et al. introduced a new minimally invasive technique for the implan-
tation of a definitive electrode.6,7 By using this electrode the duration of the sub-
chronic test phase can be prolonged and if the test results are insufficient, the elec-
trode can easily be removed. In this article we describe our clinical results with this 
new minimally invasive procedure.  
METHODS 
49 patients with symptoms of overactive bladder or urinary retention, refractory to 
conservative therapy underwent an implant procedure using the new electrode. All 
patients had a Percutaneous Nerve Evaluation (PNE) with the conventional tempo-
rary electrode before the tined lead implant.  
Under local anesthesia, in a minimally invasive procedure, a lead (Model 3889, 
Medtronic) was placed in the left or right S3 foramen.6 The lead is equipped with 
silicone tines that allow fixation in the tissue above the sacrum. Local anesthesia 
allowed for using both patients’ sensory and motor responses as a guide. The depth 
of the electrode was controlled by lateral fluoroscopy.  
The patients who had a positive result from the classic PNE had a single stage 
implant. In these patients the electrode was tunneled to an incision made at the 
ipsilateral gluteal area and connected to an extension cable.  
This extension cable is connected to an implantable pulse generator (IPG, model 
3023, Medtronic) which is inserted into a subcutaneous pocket in the gluteal area. 
The single stage procedure took on average 40 minutes. 
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The patients with inconclusive results of the classic PNE underwent a two-stage 
procedure. In these patients the lead was tunneled to a small ipsilateral gluteal 
incision. After connection to an extension cable, the lead was tunneled to a 
contralateral exit point and connected to an external stimulator (model 3625, 
Medtronic). 
The subchronic phase of the two-stage test took on average 12.4 days, (sd 5.8 days, 
5-31 days). During this phase, patients were asked to keep voiding diaries to record 
the change in their urinary symptoms. These data were compared to baseline 
voiding diaries. 
Patients with at least 50% improvement in their relevant urinary symptoms were 
implanted with an implantable pulse generator (IPG) as a second stage. In these 
patients the ipsilateral incision was reopened and the extension cable was 
disconnected and removed. A short extension cable was connected to the lead and 
an IPG was implanted. When the subchronic phase was not successful the lead and 
extension cable were disconnected and removed. The lead could easily be removed 
up to a month after implant by applying moderate traction. The first stage of the 2-
stage procedure takes on average 30 minutes, while the second stage was done in 
15 minutes. All procedures were performed under local anesthesia on an outpatient 
basis. 
After the implantation of the IPG, patients were followed on regular intervals of six 
weeks, six months and yearly thereafter.  
 
Patients were instructed to contact the clinic when they had problems relating to 
the implanted system, All patients were instructed to avoid stretching, bowing and 
bicycling for at least 6 weeks after implant. After this period the patients were en-
couraged to resume all activities that they did before the implant. Each patient with 
loss of efficacy during follow-up had an X-ray to check whether there was electrode 
migration. In June 2005 all implanted patients have been asked to fill out another 
set of voiding diaries. These diaries have been compared with the baseline diaries. 
The parameters at baseline and at last follow-up have been compared using the T-
test (SPSS 12.0 For Windows, SPSS Inc, Chicago, USA.)  
 
RESULTS 
9 of the 49 patients were male, 40 were female. The mean age was 50.0 year (sd = 
13.2 yr, range 18-73 yr). 39 patients (79.6%) were implanted for overactive bladder 
symptoms, 10 (20.4%) had urinary retention. 10 patients had a positive classic PNE 
and were implanted in a single-stage procedure. The remaining 39 patients had an 
inconclusive PNE. They were re-tested in a two-stage procedure. Reasons for the 
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inconclusive results were: discrepancy in recorded 24-hour output between the 
baseline and test period (13 patients), suspected electrode migration (7 patients) 
and technical failure of the PNE (2 patients). One patient with technical failure had a 
different anatomy due to spina bifida, in another patient the external stimulator 
switched off by itself. The other 17 patients with an inconclusive PNE had subjective 
improvement, while voiding diary analysis showed less than 50% improvement.  
In the 39 patients who underwent 2-stage testing 31 (79.5%) of the patients were 
eligible for the definitive implant and 8 (20.5%) were not.  
Of all 49 patients, 41 had a definitive implant either in a single stage or after two-
stage testing. 31 of them were included in further follow-up. 4 of the 10 patients 
who were not included had a follow-up of less than 6 weeks. A fifth patient with a 
follow-up of 18,3 months had loss of efficacy after a vaginal wall correction. A sixth 
patient died 8,9 months after implant due to a non-neuromodulation related cause 
and the seventh patient was explanted due to psychiatric reasons after 13.3 months 
follow-up, but had good results. This patient had hallucinations after implant and 
blamed adverse life events on having the nerve stimulation system.  
Three patients were lost to follow-up and did not respond to repeated requests to 
fill in an additional diary. These ten patients have been excluded from analysis.  
 
The mean follow-up of the 31 analyzed patients was 15.5 months, sd= 7.9 months. 
The follow-up ranged between 3.2 and 32.4 months. At last follow-up 28 (90.3%) of 
the patients kept more than 50% improvement in at least one of the relevant void-
ing diary parameters and 3 (9.7%) patients scored below 50% improvement. In all 
implanted patients the voided volume was increased from 153.0 ± 86.9 ml to 234.5 
± 122.5 ml at last follow-up (p = 0.000).  
 
In the patients with urge incontinence or urgency-frequency the mean number of 
voids at baseline was 11.,7 ± 8.9 voids/day. At last follow-up this decreased to 7.3 ± 
3.4 voids. (p = 0.1) The voided volume increased from 160.2 ± 70.7 ml to 231.1 ± 
119.5 ml at last follow-up (p = 0.001).  
The patients who had urge incontinence had on average 9.5 ± 8.7 incontinent 
episodes/day at baseline. At last follow-up this was 3.3 ± 2.2 episodes/day (p = 
0.17).    
 
In the 10 patients with retention the average number of catheterisations was at 
baseline 5.44 ± 1.6 caths/day and the catheterised volume was 297.6 ± 76.8 ml. At 
last follow-up the mean number of catheterisations was 1.2 ± 1.7 caths/day and the 
catheterised volume was 111.6 ± 158.,1 ml. Three of these ten patients had com-
plete retention at baseline. At last follow-up 2 of these 3 patients had a normal 
voiding pattern.  
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Six patients with retention do not catheterize any more, the remaining 4 patients 
catheterize up to a maximum of 2 times a day. The mean number of voids at 
baseline was 3.7 ± 3.8 voids/day with a volume of 123.3 ± 141.7 ml. At last follow 
up the number of voids was 4.2 ± 2.4 voids/day with a volume of 248.3 ± 146.0. 
Analysis with the T-test showed that there were no statistically significant 
differences in the parameters in patients with retention  
 
In 31 patients, 7 had a significant adverse event. Two patients had loss of efficacy 
after undergoing non-urological surgery. Both patients have positive results after up 
to 2 reprogramming sessions. Another patient with retention due to incomplete 
spinal cord lesion still has no benefit from his system. Two patients have had pain 
complaints at the IPG implant site. One had a reoperation under local anesthesia to 
reposition the IPG. The other patient had a buttock implant of the IPG, while she is 
dependent on a wheelchair. In this patient the IPG has been repositioned from the 
gluteal region to the abdominal wall. Both patients are free of pain and have posi-
tive results. A patient with positive results had an open revision because of trouble-
some leg stimulation. Investigation showed that the tined lead was placed too deep 
and stimulated the S2 nerve that is running below the level of the S3 root.  
During follow-up one incomplete electrode migration has been noted. The patient 
presented at 5.3 months follow-up with different sensations and decreased efficacy 
after a fall. An X-ray of the sacrum showed that the electrode had moved about 2 to 
3 mm in comparison to directly after the implant. The patient was successfully 
treated by reprogramming the stimulator.  
DISCUSSION 
Successful neuromodulation depends for the most part on careful selection of po-
tential candidates. Until now the only means of selecting the patients with possible 
benefit was the classic PNE. The PNE however, has its limitations. At first the dura-
tion of the subchronic phase of the PNE is limited to a maximum of approximately 
one week because of the chance of infection.  
Furthermore there is a chance of electrode migration. Edlund and coworkers men-
tioned in their study eight out of 20 patients with loss of efficacy during the sub-
chronic phase of the PNE.8 The loss of efficacy is likely due to electrode migration, 
but not in all patients with an insufficient result electrode migration could be dem-
onstrated by sacral X-ray 
 
In 1997, the 2-stage approach was introduced.9,10 Testing with a definitive electrode 
allowed for longer testing periods and decreased the chance of a negative test due 
to electrode migration. Recently Everaert et al. proved in a randomized trail that 
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testing with the 2-stage procedure gave more positive subjective results and more 
improvement in diary variables.11  
As the tined lead can be implanted in a minimally invasive procedure under local 
anesthesia and can easily be removed, testing through the 2-stage procedure be-
comes easier and is applied more often.  
The 79.5% of patients in this study who had a positive 2-stage procedure is higher 
than the 30% - 62% of positive results with the classic PNE that was found in the 
literature.8,11-14 This comparison is not entirely fair because a group of non-
responders have been filtered out by the classic PNE. 
It does show that about 20% of the negative classic PNE’s is false negative, possibly 
due to the fact that the testing period was too short to show clear results or maybe 
due to undetected electrode migration. In a recently published study Kessler et al 
showed a statistically significant difference between 50% positive responders after 
a period of 4 to 7 days compared to 80% after at least 14 days.15 These results indi-
cate that the duration of the test period plays an important role in the selection of 
potential candidates for sacral neuromodulation. It would be interesting to 
compare the results of the PNE and the two-stage tined lead in a randomized  
prospective trial.      
 
The patients with urgency show significant improvement at last follow-up com-
pared to baseline. Although patient with retention improve, the parameters have 
not changed significantly. The group of retention patients is small and most patients 
had no complete retention at baseline. 
The differences in number of voids and voided volume are relatively small, 
accounting for high p values. However the number of catheterizations has dropped 
to a mean of one catheterization per day and the need to catheterize is bothersome 
for the patients. 90% of the implanted patients keep a favorable result during the 
follow-up. This could suggest that, in addition to a better selection, placing the 
definitive lead implant under local anesthesia gives a higher chance of lasting 
positive results than the open implant.  
Minimally invasive lead placement occurs under both sensory and motor responses, 
rather than only motor responses in the open procedure. We suspect that the use 
of sensory responses in addition to motor responses provides for better electrode 
placement and therefore less chance of complications and therapy failure. This has 
yet to be confirmed in a study with larger groups of patients and a longer follow-up 
period.  
 
One patient had an incomplete electrode migration after a fall. We made sacral 
radiographies in each patient with loss of efficacy. Despite this rigorous screening 
policy, only one migration of about two to three mm was found, which could be 
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treated conservatively. Kessler et al. described one patient with bilateral electrode 
migration, who was successfully treated by reprogramming.16  
 
Two patients needed a reoperation due to pain at the IPG implant site. 
One patient uses a wheelchair and the IPG implanted in the gluteal area caused 
discomfort due to the pressure of the wheelchair on the region of the implanted 
IPG. After repositioning the IPG in the abdominal wall, the patient is free of 
complaints. Therefore abdominal placement of the IPG should be considered in 
wheelchair bound patients. In the other patient with pain at the position of the IPG, 
we found during re-operation a subcutaneous nerve running through the pocket 
wall. After repositioning the IPG away from the nerve the patient was free of 
complaints.  
CONCLUSION 
The new minimally invasive approach for sacral neuromodulation is easy to perform 
compared to the classic open method. It gives positive results on both the short and 
medium term. Two-stage testing with the tined lead appears to be a more reliable 
testing method than the classic PNE because of a prolonged testing period and 
maybe due to a decreased risk of electrode migration. Therefore testing with a 
tined lead is a useful testing alternative in patients with an inconclusive result of the 
PNE. As there was only one lead migration during median term follow-up up to 3 
years, it is obvious that that the lead anchoring method is sufficient for fixation of 
the electrode. However, long-term follow-up data on the tined lead performance 
and possible migration are not yet available.  
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Chapter 6 
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patients with OAB syndrome a feasible 
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ABSTRACT 
Sacral neuromodulation (SNM) of the lower urinary tract has proven to be safe and 
effective in patients with complaints of OAB syndrome who are not responding to 
conservative therapy. After five years of treatment the implanted system is still ef-
fective in 56-71% of patients. The loss of effect could be caused by adaptation of 
the nerve system to prolonged stimulation of the sacral nerves. We set up a pilot 
intervention study. After a run-in period of two weeks all patients were randomized 
into two groups: one group with on-demand neuromodulation (intervention group) 
and one group with continuous neuromodulation (control group). For the remaining 
two weeks, the patients in the intervention group were instructed to switch their 
INS off by default and to switch it on again when they felt recurrence of symptoms. 
The patients in the control group were asked to use their system as normally. 10 
out of 16 subjects reported a comparable symptom score during on-demand use of 
their neuromodulation system. Patients appreciated the comfort of being self-
determent in the need for therapy. Possible benefits for patients could be: more 
autonomy, longer battery life of the implanted INS, decreasing the risk of adapta-
tion by the nervous system. 
INTRODUCTION 
Sacral neuromodulation (SNM) of the lower urinary tract has proven to be safe and 
effective in patients with complaints of OAB syndrome who are not responding to 
conservative therapy.1,2 SNM treatment is also used in patients with non-
obstructive urinary retention and as an off-label treatment in patients with intersti-
tial cystitis.3 After five years of treatment the implanted system is still effective in 
56-71% of patients.4 The system consists of an implanted lead, stimulating the sac-
ral nerves through one of the sacral foramina (preferably S3), connected to an im-
plantable neurostimulator (INS) Typical battery life is 8-10 years; depending on the 
parameters used for stimulation. The expected lifespan of the recently introduced 
“Interstim II” lies around 3-5 years when used 24 hours/day. 
Most of the patients with an implanted neuromodulation system for urinary 
complaints receive continuous neuromodulation 24 hours a day. However, they are 
instructed to turn the INS off at certain moments, for example when driving a car or 
working with heavy machinery. This is to prevent accidents caused by reactions to 
sudden changes in the electrical current. 
Until now evidence is lacking whether it is necessary to apply 24 hours of 
neuromodulation per day or if discontinuation of neuromodulation is possible for a 
short period of time. 
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In early trials on SNM the effect of prolonged discontinuation of neuromodulation 
for at least 72 hours showed return to baseline of voiding symptoms in all patients. 
This was reversible in most patients by turning the neurostimulator on again.1, 5 
 
The working mechanism of SNM is not fully understood, but seems to involve 
modulation of spinal cord reflexes and brain networks by peripheral afferents, 
rather than direct stimulation of the motor response of the detrusor muscle. SNM is 
proposed to activate or “reset” somatic afferent inputs that play a pivotal role in 
the modulation of sensory processing and micturition reflex pathways in the spinal 
cord.6,7 Furthermore, there are indications that SNM influences brain areas that are 
involved in detrusor hyperactivity, awareness of bladder filling, the urge to void and 
the timing of micturition.8, 9  
With on-demand rather than continuous neuromodulation, the physiological 
situation is more adequately approximated, since in the normal physiological 
situation there is no continuous tonic afferent information coming from afferents to 
the dorsal sacral horn. Therefore, patients are expected to have a lower risk of 
developing side effects of sacral neuromodulation such as gastrointestinal 
complaints, pain or menstrual cycle changes.  
Clinical experience as well as the literature on SNM has shown that a certain 
percentage of implanted patients stop having benefit from their implanted system 
after a few years, despite adequate neuromodulation. A suggested hypothesis for 
this phenomenon is adaptation of the nerve system to prolonged stimulation of the 
sacral nerves.10 It could be expected that on-demand neuromodulation postpones 
or diminishes this effect.  
The objective of this prospective pilot study was to investigate whether the on-
demand use of SNM is a feasible therapy regime, therewith mimicking the normal 
physiological situation as well as diminishing the need for frequent replacement of 
the INS. 
PATIENTS AND METHODS 
This study was set up as a pilot intervention study. Patients who were treated with 
SNM for symptoms of urgency incontinence or urgency-frequency syndrome refrac-
tory to conservative therapy were included. Patients were considered eligible for 
the study when they had a functioning neuromodulation system with unchanged 
stimulation settings for at least six months. All participants were implanted with a 
system that includes a patient programmer, which gives the possibility to deactivate 
the system (Medtronic Interstim model 3023 and Model 3031A patient program-
mer, Medtronic, Minneapolis MN, USA). Patients with relevant co-morbidity were 
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excluded (e.g. urinary tract infection, non-functioning system, malignancy of the 
urinary tract).  
For this study a hybrid design was followed, based on previous work by Pocock.11 
Instead of a 50:50 allocation of patients, we randomized 25% of the participants to 
control, permitting 75% to be assigned to the new intervention. We started with all 
patients and follow them for two weeks to establish a firm baseline (and the 
knowledge that with continuous SNM there will be maximum “on” time and very 
likely no change in symptoms). After two weeks patients were randomized to the 
on-demand group, while 5 stayed in the continuous (control) group. At the end of 
study, the data from the controls were compared to the baseline group and showed 
stability. This allowed us to combine all controls and compare them to the on-
demand group. This enabled us to perform a transversal comparison with a 
minimum of patients. The main criteria for such an approach (rather recent 
included patients, the same procedure and investigator and identical outcome 
assessments) were all met in this trial. 
All included patients signed an informed consent and were asked to register a 
voiding diary for two weeks (baseline) and to fill out a urologic measurement 
questionnaire (UMQ). This UMQ measures subjective urologic complaints in 
patients. This questionnaire is previously used in other studies regarding SNM for 
the measurement of subjective complaints.12 This UMQ consists of seven questions 
on urologic complaints; a score of 1 (much worse) to 5 (much better) can be given 
to each of the questions (Appendix 1). The questionnaire is previously used in other 
studies regarding SNM for the measurement of subjective complaints.12   
This questionnaire was chosen because it has been used in our practice since the 
start of our neuromodulation database and appeared to be very useful in clinical 
practice and follow-up of individual patients. Although it is not a validated 
questionnaire, it gives a comparable scale of subjective complaints. We consider the 
data of interest to the clinician. as they give an impression of the magnitude of 
change.  
The total study duration was four weeks. We started with a run in period of two 
weeks: in this period all subjects registered a voiding diary (baseline symptoms). At 
the end a urogical questionnaire had to be filled out. After the run-in period of two 
weeks all patients were randomized into two groups: one group with on-demand 
neuromodulation (intervention group) and one group with continuous neuro-
modulation (control group). For the remaining two weeks, the patients in the 
intervention group were instructed to switch their INS off by default and to switch it 
on again when they felt recurrent symptoms. So when they experienced more 
urgency symptoms or incontinence they turned their INS on. When symptoms had 
disappeared they could turn the INS off again. The patients in the control group 
were asked to use their system as normally: this means they were not allowed to 
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change settings during the trial. At the end of this period, subjects were asked to fill 
out the UMQ again. (appendix 2) 
With a voiding diary urinary complaints as well as the on and off hours were 
registered for both groups. The following voiding diary parameters were evaluated: 
number of voids/24h, voided volume/void, number of leakages/24h, number of 
pads/24h and the degree of urgency. 
On-demand neuromodulation was considered successful when patients were able 
to switch the INS off for at least 4 hours per day, without worsening of urinary 
symptoms recorded with voiding diaries and UMQ. This cut-off point was set at 4 
hours because this was considered a time span that could give a relevant change in 
battery lifespan. 
Institutional review board approval was obtained for this study. All included 
patients signed an informed consent. Data analysis was performed using Statistical 
Package for the Social Science version 12.0 (SPSS Inc., Chicago IL, USA).  
RESULTS 
In total 26 patients were included in this study. Five patients were excluded from 
analysis because they did not fill out the voiding diaries correctly.  
Complete voiding diaries were obtained of the remaining 21 patients, who were 
randomized into two groups. Five patients were randomized into the control group, 
16 into the on-demand group. In the on-demand group there were 2 men and 14 
women, in the control group only women. The mean age of these patients was 53.6 
years. All patients had their neuromodulation system implanted between 1992-
2004 for urgency incontinence. By the time they were participating in this study an 
Interstim model 3023 was implanted. In all patients the INS configuration was 
unchanged in the last half year and all subjects were capable of using their patient 
programmers correctly.  
Baseline symptoms for both groups with continuous neuromodulation are shown in 
table 1. There were no statistical differences in baseline parameters between the 
two groups.  
 
Table 1. Baseline symptoms for both groups. 
 Pads/day Volume/void #micturition/day #leakages/day 
On Demand 0.9 131 ml 8.7 2.9 
Control 1.1 202 ml 7.3 2.8 
 
In the control group no differences were observed between the results of voiding 
diaries and UMQ during the first two weeks (baseline) and the second 2 weeks of 
this study. In the intervention group 10 of 16 subjects reported a comparable 
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symptom score (no worsening) during on-demand use of their neuromodulation 
system. They had a mean off time of 12.4 hours a day.  
 
Table 2. shows the mean off-times in hours a day for the intervention group.  
 
Table 2. Number of patients with off-hours/day during intervention period. 
Mean off-times in hours a day for the intervention group 
Modulator off (hrs) Worsening No Worsening Total 
4-14 0  2  2 
14-24 6  8 14 
Total 6 10 16 
 
The six patients in the on-demand group that had worsening of symptoms were all 
patients who were symptom free during continuous use of their SNM system. With 
on-demand use of their system they experienced symptoms again. In these patients 
there was no difference in age.  
 
Table 3 shows the different parameters for the subjects of the intervention group.  
 
Table 3. micturition parameters during intervention period (mean off-time per day in hours). 
No. Pts.  
Increase 
(Not succesful) 
No Increase 
(Succesful) 
Voids / 24 hr 4 (10h)  12 (18h) 
Leakage episodes 6 (8.4h) 10 (12.4h) 
Pad use 6 (8.4h) 10 (12.4h) 
Severity of leakage 4 (10h) 12 (18h) 
 
After the intervention period all participating subjects filled out a Urologic Meas-
urement Questionnaire (UMQ). With this questionnaire subjective differences be-
tween both periods were measured with seven questions. (min-max score 7-35). A 
score below 17 was considered as a worsening in subjective measurements. When 
subjects experienced no difference or improvement in all symptoms they should 
have scored 21 or higher.  
 
Table 4. scores for subjective measurements (Urologic Measurement Question-
naire) 
Subjective change Control On-demand Total 
Worsening (</=17) 0  8  8 
No Worsening(>17) 5  8 13 
Total 5 16 21 
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DISCUSSION 
SNM is an approved treatment for different challenging urological conditions.1-3 
Unfortunately some patients tend to loose their initial effect over the years. Long 
term multi-centre results show an efficacy off 56-71% for the different relevant pa-
rameters at five years.4 Possible explanations for failures during use of SNM include 
the potential placebo effect of test stimulation, insufficient test stimulation sensitiv-
ity before implantation and inadequate patient selection. 
These explanations are supported by a good correlation between the one- and five-
year success rates.  
Adaptation of the nervous system, although never clearly studied, is another pro-
posed mechanism for the loss of effect on the long term for prolonged stimulation 
of the sacral nerves. On-demand neuromodulation might be an ideal way of stimu-
lation to prevent this phenomenon.  
The results in table 1 shows that 14 out of 16 patients in the intervention group had 
their INS turned off for at least 14 hr a day. 10 out of 16 patients could turn their 
INS off without worsening of complaints during this period, and 8 of these patients 
could do that for at least 14 hr. 
In this study, 62.5% of the patients in the intervention group showed no increase in 
pad use and/or number of leakage episodes a day (Table 2). Looking to the number 
of voids in a day and the severity of leakage 75% of the intervention group had no 
increase in symptoms. This means that for an average group of patients treated 
with SNM for urgency incontinence almost 2/3 could be treated with on-demand 
neuromodulation.  
In the intervention group 50% of patients experienced worsening in subjective 
symptoms. This result can be explained by the way we instructed our patient. They 
were told to the turn the INS on during the intervention period when they felt 
recurring symptoms. As expected the patients in the control group experienced no 
difference (Table 3). 
Another method of non-continuous neuromodulation is stimulation by cycling 
mode. This is possible with all implantable neurostimulators nowadays used for 
SNM therapy. With this setting the INS turns itself on and off in a preprogrammed 
cycle. For example the stimulation can be programmed on during 10 seconds and 
then off for 5 seconds.  
Disadvantages of this method compared to on-demand neuromodulation is that a 
patient experiences this on/off event every time. Most of our patients reported 
discomfort during this cycling mode stimulation. A second disadvantage is that it is 
not the patient itself that determines the need for therapy. When we asked 
patients how they experienced on-demand neuromodulation, many patients 
appreciated the comfort of being self-determent in the need for therapy. They felt 
less dependent from their neuromodulation system. However, we did not measure 
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the influence of this reported effect on quality of life. While an improvement in 
quality of life may be appreciated by some, those who are satisfied with continuous 
stimulation such that they no longer think about their prior voiding complaints, may 
view intermittent stimulation as an interruption and an impediment to their quality 
of life. 
The long-term effects of on-demand neuromodulation were not studied in this pi-
lot. Therefore long-term studies are necessary to determine if on-demand neuro-
modulation can prevent adaptation of the nervous system.  
CONCLUSION 
According to this pilot study, on-demand neuromodulation is a feasible therapy 
regime in patients with urgency incontinence successfully treated with SNM ther-
apy. Possible benefits for patients could be:  
• more autonomy; it allows patient to confidently turn of their SNM system with-
out losing efficacy 
• longer battery life of the implanted INS 
• decreasing the chance of adaptation by the nervous system. 
Nevertheless, larger, randomized controlled studies with longer follow-up are 
needed and should include quality of life measurements as well as a more detailed 
data on battery life improvement.  
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APPENDIX 1 
Urologic Measurement Questionnaire 
1. Do you think that voiding in general goes better? 
No, it’s much worse / no it’s worse / no difference / yes, some improvement / 
yes a lot better 
 
2. Do you think that your flow has improved? 
No, it’s much worse / no it’s worse / no difference / yes, some improvement / 
yes a lot better 
 
3. Does your bladder feel emptier? 
No, it feels much fuller / no, it feels a bit fuller / no difference / yes, it’s emptier 
/ yes, it’s much emptier 
 
4. Do you think you are drier? 
No, much wetter / no, a bit wetter / no difference / yes, a bit drier / yes, much 
drier 
 
5. Have your urge-sensations changed? 
Clearly worsened / a bit worse / no difference / a bit less / clearly diminished 
 
6. Has your voiding frequency changed? 
No, I had to go more often / no, I had to go a bit more often / no difference / 
Yes, I had to go somewhat less often / Yes, I clearly had to go less often 
 
7. Do you have more control over your bladder? 
No, it’s worse / No, it’s somewhat worse / no difference / yes, it’s better / yes, 
it’s much better 
 
Score 1 -5 
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APPENDIX 2: COURSE AND TIMING OF THE STUDY 
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ABSTRACT 
Objectives: To determine whether SNM for urinary symptoms or faecal inconti-
nence gives improvement of female sexual function and whether improvement is 
due to physiological factors or psychological factors.  
Methods: Between 2002 and 2008, 8 patients have had an array of questionnaires 
before and after SNM implant. The questionnaires were: the Questionnaire for 
Screening for Sexual Dysfunctions, the Golombok Rust Inventory of Sexual Satisfac-
tion, The Symptoms Check List-90, The Maudsley Marital Questionnaire and the 
McGill-Mah Orgasm Questionnaire. Three of these 8 patients underwent vaginal 
phletysmography before and after implant.  
Results: no statistically significant changes have been found, although there seems 
to be a trend toward improvement in orgasm scores. In the phletysmography all 
three patients show increased Vaginal Pulse Amplitude with the stimulator turned 
on with both erotic and non-erotic stimuli.  
Conclusions: This study does not show a clear effect of SNM on sexual function, 
although there seems improvement in orgasm scores. The lack of response on psy-
chological questionnaires and the increase of VPA after SNM implant indicate that 
there might be a physiological response.  
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INTRODUCTION 
Since the 1990’s sacral neuromodulation is used in patients with refractory idio-
pathic symptoms of overactive bladder (OAB) or non-obstructive urinary reten-
tion.1,2,3 Recently its efficacy and safety is established in patients with faecal incon-
tinence and constipation as well.4,5 Sacral neuromodulation (SNM) is carried out by 
electrical stimulation of one of both nerve roots running from both third sacral fo-
ramina. 
During routine follow-up for SNM with the Interstim system in our outpatient clinic 
a number of female patients spontaneously reported improved sexual functioning 
in comparison to before their SNM implant. In the current literature, little is known 
about the relationship between SNM for urinary symptoms and possible impact on 
sexual functioning in female patients.  
Sensory innervation of vagina and uterus is supplied through the pudendal nerve 
(external genitalia and clitoris), hypogastric nerve and pelvic nerve (both innervate 
the vagina and uterus). The pudendal nerve runs from the sacral plexus and 
contains fibers from S2, S3 and S4. The hypogastric and pelvic nerves contain 
sensory, sympathic and parasympathetic fibers. The pelvic nerve has fibers derived 
from S2, S3 and S4 as well. Moreover, the lumbosacral spinal cord contains in-
terneurons that modulate the spinal sexual reflexes.6 A suggested hypothesis of the 
mechanism of action of SNM on lower urinary tract symptoms (LUTS) is modulating 
interneurons responsible for regulating the voiding reflex through stimulation of C-
afferent fibers.7 Based on the anatomical proximity and functional similarities of the 
sacral voiding and sexual nuclei, SNM might have a beneficial physiological effect on 
the sexual organs in female patients.  
However, having lower urinary tract or bowel symptoms as described above has a 
marked negative influence on the quality of life of the patients, and successful SNM 
is known to increase quality of life.8 By feeling more comfortable, the interest in 
and the pleasure derived from sexual activities might increase in patients. 
Resolution of urinary or faecal symptoms can make these patients more 
comfortable and confident in their sexual relations.  
This study is carried out to: 1. Objectify whether SNM for LUTS or faecal 
incontinence does improve sexual function in female patients. 2. Determine 
whether improvement is due to a direct physiological response to SNM or because 
of improved well-being due to symptom resolution.  
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MATERIAL AND METHODS 
Permission for this study was obtained from the Medical Ethical Committee of the 
University Hospital Maastricht. Female patients aged between 18 and 60 years with 
urgency incontinence, urgency-frequency, non- obstructive urinary retention or 
faecal incontinence who were planned to undergo SNM implant with an Interstim 
system (Medtronic, Minneapolis, USA) were asked to participate in this study. Pa-
tients had to be sexually active with a partner and had to be able to read, compre-
hend and complete questionnaires written in Dutch. All participants had given writ-
ten informed consent.  
Patients with a known neurological cause for their voiding symptoms or with one of 
the other known contraindications for SNM, including obstructive voiding disorders, 
anatomical sacral defects, urinary tract infections, severe genitourinary prolapse, 
skin infections at the surgical site, malignancy of the urinary tract or anorectal 
malignancies, were excluded.  
 
The subjects had either undergone a successful conventional Percutaneous Nerve 
Evaluation (PNE) test or were planned for a 2-stage procedure for their com-
plaints.9,10 Patients who underwent the 2-stage procedure filled their baseline ques-
tionnaire in before the 1st stage and were not included when the 1st stage proved 
not successful. Therefore all included subjects had 50% or more improvement in 
relevant voiding or defaecation diary parameters during the trial phase and were 
eligible for a definitive SNM system implant. Voiding and defaecation diary analysis 
before and after implant of the SNM system has been performed.  
 
All participants filled out an array of written psychological questionnaires before 
and after definitive implant of their SNM system, consisting of the Questionnaire for 
Screening for Sexual Dysfunctions (QSD; Vroege, 2001), the Golombok Rust Inven-
tory of Sexual Satisfaction (GRISS),11,12 The Symptoms Check List-90 (SCL-90),13 The 
Maudsley Marital Questionnaire (MMQ)14,15 and the McGill-Mah Orgasm Question-
naire.16 All questionnaires were supplied in Dutch, native language of all subjects. 
The patients filled these lists in at home at their convenience. The questionnaires at 
baseline were accompanied with a small questionnaire on demographic data and 
specific sexual history. In the sexual history questions were asked about current 
complaints, past important sexual experiences, pregnancy and labour, and influence 
of the complaints on sexuality and relation with the partner.   
The QSD questionnaire asks about several types of sexual dysfunction and is both 
physiologically and psychologically oriented. The chosen subdomains are Desire, 
Arousal, Orgams and Pain. In addition, a rating of the perceived impact of the 
dysfunction on subjects’ functioning is given. Until now, there are no standard 
scores available of the QSD in the general population. 
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The SCL-90 is an instrument for screening for psychopathology and is widely used in 
research to measure patient well-being after interventions.17 
In the McGill-Mah Orgasm questionnaire patients are asked to rate words that 
might be applicable to their perception of orgasm on a 5-point scale. The subjects 
had a list of adjectives for orgasms, achieved through sex with a partner and 
orgasms realized by masturbation. The scores are divided in three main groups; 
Evaluative, Affective and Sensory. In the Evaluative domain all cognitions of orgasm 
are summarized, while Affective is the domain for the emotional aspects of orgasm. 
The Sensory domain describes the somatic aspects of orgasm. 
The Maudsley Marital Questionnaire measures marital dissatisfaction.  
The Golombok and Rust Inventory of Sexual Satisfaction questionnaire measures 
sexual dysfunction and has subscales dealing with physiological effects and 
emotional effects such as avoidance behaviour. 
 
The initial study protocol described measurements of the Vaginal Pulse Amplitude 
through vaginal plethysmography.18,19,20 Patients were given visual sexual and neu-
tral stimuli in a visually enclosed environment, while through vaginal plethysmogra-
phy the Vaginal Pulse Amplitude (VPA) was measured. A total of five erotic video 
fragments with audio, each lasting 330 seconds, were shown to each patient in two 
measurement sessions. The fragments were from a female-centered erotic movie 
and randomly alternated with neutral, ie. non-erotic videos. Two video fragments 
were shown at the measurement session before SNM implant, three fragments in 
the measurement session after SNM implant. The patients were asked to express 
levels of subjective sexual excitement during the stimuli by turning a dial, calibrated 
to a 100-point scale. In the measurement session after implantation measurements 
were made with the SNM system switched on and off. The off-measurement was 
made 20 minutes after switching the SNM system off.  
In contrast with the Vaginal Blood Volume (VBV), the VPA is indicative for rapid 
changes in vaginal vasocongestion and regarded as a more sensitive and specific 
index for physiological sexual arousal.21 Serum progesteron, 17- Β-oestradiol and 
testosteron was measured to determine in which phase of the menstrual cycle the 
subjects were in at time of measurement.  
The plethysmograpic data was amplified and analyzed with a personal computer. 
The VPA was defined as the mean and maximum difference between the vaginally 
measured heart pulse amplitude in a sample block. The mean VPA was calculated 
over segments of 30 seconds. The first 60 seconds after start of a stimulus were 
considered a run-in period and were not analyzed. The highest VPA during the 30 
second block was designated as the maximum VPA. The acquired data was visually 
inspected for movement artifacts, which were excluded from further analysis.  
The difference between the mean and the maximum VPA at baseline and with the 
SNM system implanted were calculated.  
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Several subjects withdrew their informed consent when being confronted with the 
measurement setup and inclusion of study subjects was very slow.  
Therefore the plethysmography protocol was abandoned after three patients. 
 
Statistical analysis was performed with SPSS 17.0 (SPSS, Inc., Chicago, Il.) Differ-
ences between scores before and after SNM were tested for statistical significance 
with the Mann-Whitney test. Analysis of the data showed that the data was not 
normally distributed. Data were described as median and range, considering the 
small amount of study subjects. 
RESULTS 
A total of 10 patients were included between January 2002 and December 2008 and 
had a successful PNE or 2-stage procedure. One patient filled in the questionnaires 
at baseline, but was explanted due to infection before the second set of question-
naires could be administered. She was excluded from the study. Another patient 
refused further participation in the study after the baseline questionnaires were 
taken and was excluded from analysis as well. Eight patients were ultimately ana-
lyzed.  
Median age of these 8 patients was 53.5 years (range 21- 61). Six patients had 
urinary urgency symptoms, one patient suffered from urinary retention and one 
patient had faecal incontinence. Median duration of their complaints was 6.5 years 
(range 2.0 – 36.0). All patients had satisfactory results of their definitive SNM 
implant.  
All patients were heterosexually oriented and were sexually active during the study 
period. All patients but one had a steady relationship. The partner of one patient 
had suffered from a stroke before patient enrolled in this study, but the couple was 
still sexually active. One patient reported an unpleasant sexual experience in her 
past. Six patients were postmenopausal. One patient had a Wertheim-Meigs 
procedure because of cervical carcinoma. When asked ‘do you have any current 
sexual complaints?’ on the history form at baseline, only one of the patients 
answered affirmative.  
 
The results at baseline and post implant of the Questionnaire for screening Sexual 
Dysfunctions (QSD) are shown in table 1. The ranges between lowest and highest 
scores are high, signifying large differences in QSD item scores between subjects in 
this small group. There is a small increase in the occurrence of genital pain after 
SNM implant.  
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The median of 0 with a range of 9.5 is explained by the fact that five patients out of 
eight report no genital pain and three patients do with scores of 1.0, 5.0 and 9.0.  
There is no difference in the orgasm score before and after SNM, but the decrease 
in range indicates that in patients reporting high dysfunction scores before SNM the 
dysfunction decreases, therefore approaching the patients who already reported 
little dysfunction. The sum score of the QSD shows a small overall deterioration in 
the group of patients, but the range increases as well. Because of the small sample 
size no statistical significance could be found.  
 
Table 1. The results of the Questionnaire for screening Sexual Dysfunctions (QSD).  
Results of the QSD before and after SNM implant 
 Baseline Post SNM implant 
 Median Range Median Range p 
Desire 5.10 8.80 4.85 8.80 0.944 
Arousal 3.00 28.00 3.67 28.00 0.959 
Orgasm 2.33 12.67 2.33 9.67 0.645 
Pain  0.00 9.50 0.50 9.00 0.878 
Total 11.42 7.53 13.65 55.47 0.959 
Median scores and range (difference between the highest and the lowest score) of baseline (before SNM 
implant) and post-implant are shown. The p-values are shown as well. A higher score means more dys-
function 
 
Table 2 shows scores on the SCL-90 before and after SNS implant. Anxiety, depres-
sion, and problems in interpersonal sensitivity were decreased after implant, but 
the differences were not statistically significant. Agoraphobia and somatic problems 
remained equal. In agoraphobia the range decreased by four points while in so-
matic problems the range increased by five points. The decrease in the range of the 
agoraphobia score is caused by a decrease in patients who scored relatively high at 
baseline. In addition, the score in patients with low agoraphobia scores is consid-
ered a floor effect. A small increase in a low agoraphobia score will not be meas-
ured by the SCL-90. The increase in range in the somatic problem score is explained 
by an outlier scoring 22 points. The SCL-90 total score is slightly decreased. Consid-
ering the overall low mean level of psychopathology, the small change effects might 
be considered a floor effect.  
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Table 2. SCL-90 scores before and after SNM implant.  
Results of the Symptom Check List-90 before and after SNM 
 Baseline Post SNM implant 
 Median Range Median Range p 
Anxiety 12.50 9.00 11.00 8.00 0.279 
Agoraphobia 7.00 7.00 7.00 3.00 0.959 
Depression 20.00 26.00 18.50 23.00 0.878 
Somatic problems 14.50 18.00 14.50 23.00 0.959 
Insufficiency 10.50 14.00 11.00 13.00 1.000 
Interpersonal sensitivity 23.00 20.00 20.50 13.00 0.721 
Hostility 6.50 2.00 6.00 3.00 0.328 
Sleeping problems 4.50 7.00 4.00 8.00 0.959 
SCL-90 total 109.50 105.00 102.50 79.00 0.798 
Median scores of the subscales of the SCL-90 before and after SNM implant and p-scores are shown. 
Higher scores reflect more symptom perception.  
 
Analysis of the scores of the Maudsley Marital Questionnaire shows no changes on 
dissatisfaction in all three items (relational dissatisfaction, sexual dissatisfaction and 
dissatisfaction in general life.) Therefore the data are not shown in a table.  
 
The results of the McGill Mah Orgasm Questionnaire are shown in table 3. 
One patient stated that she does not masturbate, therefore she is excluded from 
analysis of the McGill Mah questionnaires. A trend towards improved orgasmic ap-
preciation in nearly all domains, both with partner as orgasm achieved through 
masturbation is implicated by the findings, but no significant p-values have been 
measured. The sensitive with partner domain is decreased with one point.  
 
Table 3. The results of the McGill Mah Orgasm Questionnaire for sex with a partner and for masturbation 
before and after SNM implant in seven patients. 
Results of the McGill Mah Orgasm Score before and after SNM 
  Baseline Post SNM 
  Median Range Median Range p 
Masturbation Sensitive 18.0 37.0 23.0 26.0 0.383 
 Affective  19.0 31.0 23.0 26.0 0.456 
 Evaluative  15.0 21.0 19.0 18.0 0.383 
Partner Sensitive 42.0 60.0 41.0 43.0 0.805 
 Affective  36.0 41.0 38.0 24.0 0.902 
 Evaluative  24.0 22.0 25.0 11.0 0.8057 
 
Table 4 shows the scores regarding sexual dysfunction and dissatisfaction (GRISS) 
before and after SNM. Improvement with regard to sexual functioning appears to 
be reported on some subcategories, namely infrequency and dissatisfaction. 
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The other scores do not seem to change. The total score seems to improve. Statisti-
cal analysis shows no statistical significance in these differences.  
 
Table 4. Results of the Golombok and Rust Inventory of Sexual Satisfaction.  
Results of the GRISS before and after SNM 
 Baseline Post SNM 
 Median Range Median Range p 
Infrequency 7.50 8.00 5.50 7.00 0.328 
Noncommunication 4.00 6.00 4.50 5.00 0.878 
Sexual Dissatisfaction 7.50 12.00 6.00 13.00 0.574 
Avoidance 5.00 10.00 5.00 10.00 1.000 
Nonsensibility 5.00 14.00 5.00 10.00 0.798 
Vaginismus 4.50 13.00 4.50 14.00 0.878 
Anorgasmia 9.50 13.00 9.50 11.00 0.959 
Griss Total 52.50 74.00 51.00 76.00 0.878 
Median scores, range and p-values of baseline and post SNM-implant are shown. A higher score signifies 
more dysfunction. 
 
Three patients underwent measurement with vaginal plethysmography before and 
after SNM implant. One patient (61 years old) was suffering from urgency inconti-
nence, one (60) had faecal incontinence and one (21) had urinary retention. Graphic 
1 shows the mean VPA of the measurements in these three patients. There is no 
statistical significance in the changes in VPA in these three patients. There is, how-
ever, a trend towards increased mean VPA response after SNM implant. Even when 
the subjects are watching a neutral video or when the stimulator is off during an 
erotic video, mean VPA is higher than before SNM. This might imply an enduring 
effect of SNM on pelvic vasocongestion, that is not dependent on sexual stimuli. 
The subjective measurement of sexual arousal, measured with a calibrated dial, 
remained low in all three patients and did not change after SNM implant.  
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Average Vaginal Pulse Amplitude with visual stimuli before and with SNM implant
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Figure 1. Mean VPA measurements with erotic and neutral visual stimuli of the three subjects before and
after SNM implant. The changes are not statistically significant. 
DISCUSSION 
This study was initiated because at routine follow up visits of patients with SNM 
several female patients spontaneously reported improvement in their sexual func-
tioning. The results of this study do not clearly support the improvement men-
tioned by several of our patients.  
However, there are several other studies on the influence of SNM on the female 
sexual function where significant positive results were found.  
Pauls et al. reported improvement in the FSFI (Female Sexual Function Index) score 
in eleven female patients with a SNM implant for LUTS.22 Significant improvement 
with regard to sexual desire was found in all patients in that study. There was a 
significant difference in seven of those eleven patients with regard to lubrication, 
orgasm and pain. Interestingly, all patients in Pauls’ study improved on the FSFI, 
while only three subjects reported subjective improvement of sexual functioning.  
In 2008 Lombardi et al. presented the results of their study on the effect of sacral 
neuromodulation on sexuality in 31 female patients. In this study both patients with 
idiopathic and with neurological causes for their LUTS were included. Improvement 
in FDSF (Female Sexual Distress Scale) and FSFI after SNM was found in both patient 
groups.23  
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Another study on the effects of SNM for LUTS on female sexual function was carried 
out by Zahibi et al.24 Characteristics of this study were: a large proportion of the 
patients had pelvic pain as well as LUTS. The study group chose to perform bilateral 
SNM and to position the electrodes epidural in the sacral canal, thus stimulating the 
nerves of S2 and S4 as well as S3.  
A significant improvement in the FSFI was found. Domains with no significant 
improvement were: ‘desire’ and ‘pain’.  
Ingber et al used the FSFI questionnaire on 54 female patients who were scheduled 
to receive an neuromodulation implant. They administered the FSFI before neuro-
modulation implant and six months after implant and found non-significant im-
provements in female sexual function after implant.25 Only half of their analyzed 
population was sexually active. Both neuromodulation by sacral neuromodulation 
and by pudendal implant techniques was used in their study.26  
In one study, published in 2009, Jarrett et al. administered a self-written sexual 
questionnaire to patients with fecal incontinence before and after their SNM 
implant. In 9 sexually active patients (of 16 patients) an average of 36,7% improve-
ment (range 0 – 100%) in reported sexual functioning.27 
The increase in pain scores in the QDS in this study might be explained by the fact 
that these patients are measured at six weeks after the implant and are not 
experienced yet with adjusting the stimulation amplitude with the remote control 
that each patient receives after implant on an SNM system.  
In the study by Pauls et al. subjective improvement is seen in all the stages of the 
sexual response cycle except for arousal.  
Sexual arousal is a response to a sexually attractive stimulus and has both a 
physiological and a subjective component. Many people define arousal as the 
feeling of sexual attraction, which in the sexological literature is referred to by the 
term desire. The results of our study show a trend towards improvement in desire 
to engage in sexual activity after SNM. In this article we define sexual arousal as the 
genital and subjective responses to erotic stimulation when engaging a sexual 
encounter. In this study a trend towards deterioration of subjective arousal is found 
in the QSD, but improvement of vaginal vasocongestion with SNM was measured, 
regardless of the kind of stimulus. Vaginal vasocongestion is one of the main genital 
components of sexual arousal in female patients.  
In the literature is evidence that the concordance between physiological genital 
arousal and the perceived arousal by females is low, compared to the concordance 
in men.28,29 The reason for this phenomenon is still unclear. A suggested hypothesis 
is that genital arousal in men, i.e. erection, gives more sensory and visual feedback 
to the male than the genital response does in the female.  
 
In the three patients measured with vaginal phletysmography our study we found 
clues for a discrepancy between physiological improvement and psychological dete-
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rioration of sexual arousal. In contrast, Pauls et al.22 found improvement in arousal 
in their study. An explanation of this discrepancy might be that SNM improves vagi-
nal vasocongestion during the arousal phase, but this is not perceived by the 
women. This might explain why Pauls et al. did not find improvement in their ques-
tionnaire-based study. In the current study no improvement was reported in the 
questionnaire part. 
 
The SCL-90 shows a nonsignificant decrease in symptom perception. Interpersonal 
sensitivity is the symptom that shows the most reaction to SNM. The improvement 
in interpersonal sensitivity might be explained by the decrease of worries about 
hygienic problems and incontinence pad use. As a result of this patients can interact 
with other persons more freely. The decrease in anxiety and hostility can be consid-
ered as confirming this hypothesis. The observed absence of further improvement 
with regard to psychopathology may be due to the low baseline level of these prob-
lems. 
 
Most convincing is the trend towards improvement in the McGill-Mah Orgasm 
scores. The perception of patient’s orgasm both with and without partner increases 
in all three domains. In the QSD orgasm scores remain equal between the two 
measurements The QSD is a diagnostic tool for perceived dysfunction and therefore 
might not adequately measure improvement in patients with little or no dysfunc-
tion, while the McGill Mah score might be more sensitive for these effects. 
There are case reports on female patients who receive lumbal epidural electro-
stimulation for non-sexual complaints, who have spontaneous orgasms when the 
stimulator is turned on.30 Patients with a definitive SNM system implant have a re-
mote control, enabling them to adjust stimulation amplitude. Until recently patients 
were advised to set stimulation amplitude that the stimulation is felt, but not in an 
unpleasant way. Most female patients feel the stimulation in the genital area. As far 
as we know, there have never been reports of patients having spontaneous 
orgasms while receiving SNM therapy or while undergoing an acute PNE or two-
stage procedure. A recent publication by Baeten et al. shows that SNM has an effect 
on uterus contractility.31 A decrease of frequency of contractions is seen with the 
SNM system switched on. But as the measurements have been performed in 
patients in resting state, it is not clear what the effect is of SNM on the uterus while 
the patient has an orgasm.  
 
The three patients who underwent plethysmographic measurements with erotic 
and neutral stimuli before and after SNM all show a (non-significant) increase in 
VPA after SNM implant. They do not report a difference in subjective arousal while 
watching the videos before and after SNM. However, they do show increased pelvic 
blood flow in the plethysmographic measurements. This trend towards increased 
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mean VPA is present, influenced by neither the kind of stimulus (erotic or neutral) 
nor the on or off-modus of the stimulator. SNM might have a general enhancing 
physiological effect on pelvic blood flow, and therefore might improve sexual func-
tioning.  
In the current literature on SNM there is no evidence found for the effect on SNM 
on pelvic blood flow. The increase in pelvic vasodilatation may be caused by 
stimulation of parasympathetic fibers by SNM.  
When looking at the data of the questionnaires and the discrepancy between 
objectively measured VPA and subjective arousal in this prospective study and at 
the available literature on SNM and female sexual functioning, there are clues that 
SNM may give an improvement in sexual function in female patients. This 
improvement seems to be mostly because of a psychophysiological effect and for a 
lesser part due to an improved well-being.  
 
None of the results in this study was statistically significant. The most obvious cause 
for non-significance is the low number of patients tested. Recruitment of study sub-
jects was very slow. Several study subjects withdrew their consent because of the 
plethysmography. To give an impulse to recruitment, the plethysmography protocol 
was abandoned. After that recruitment still was slow. A reason for this might be 
that many patients with prolonged LUTS or fecal symptoms are not sexually active 
(any more) because of their complaints, while an inclusion criterion of this study 
was current sexual activity. Therefore a selection bias might have been introduced, 
that could not have been avoided, since non-sexual active patients could not par-
ticipate in the measurements. In the study by Ingber et al, where sexual activity was 
not an inclusion criterion, half of the patients were not sexually active when ana-
lyzed. Moreover, a large proportion of the group of patients that have urinary or 
fecal symptomatoloy and are considered for SNM therapy are postmenopausal pa-
tients. In this group considerable co-morbidity can be found such as hysterectomy, 
vascular disease, diabetes or arthrosis that might also preclude patients from en-
gaging in sexual activity. Furthermore, our results show relatively low levels of sex-
ual pathology, and the ceiling effects or floor effects might not be measured with 
our questionnaires. In their article Pauls et al. reported slow subject recruitment as 
well.  
Another reason for non-significance is that our population is heterogeneous. Three 
different diagnostic categories have been included, namely, urgency incontinence, 
urinary retention and faecal incontinence. Furthermore the sample has been het-
erogeneous with regard to pre- or postmenopausal status, co-morbidity, and coping 
strategies. 
Nevertheless, this is the first prospective study in which vaginal plethysmography 
was used to investigate the nature of the improvement in sexual function in female 
patients with SNM.  
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Further research into this interesting field would ideally be a multicentre study to 
accumulate sufficient patients for statistical analysis and even subgroup analysis. 
Also, a study which compares the prevalence of sexual dysfunction within these 
patient groups to age-matched patients without LUTS or faecal incontinence could 
be very interesting. Research might also be directed into the comparison of im-
provement of sexual function between patients with SNM versus other therapies, 
for example intravesical botulin toxin injection, to differentiate between a direct 
physiologic mechanism of SNM versus a psychological action because of decrease of 
symptoms on sexual functioning. Another research project would be investigating 
whether SNM does indeed increase pelvic blood flow and therefore has a physio-
logical effect on sexual functioning. Also the occurrence of improvement of sexual 
function in male patients with SNM could be studied, as males show more concor-
dance between physiological versus psychological arousal. However, in our patient 
population we have no reports of male patients with improvement of sexual func-
tioning after SNM.  
CONCLUSION 
The results of this study suggest there might be sexual improvement in female pa-
tients receiving SNM therapy for urgency symptoms, urinary retention or faecal 
incontinence. This improvement seems to be more physiologically than psychologi-
cally mediated. 
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Chapter 8 
Discussion and future perspectives 
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Lower urinary tract symptoms have a significant impact on the quality of life of af-
fected persons.1 Before the introduction of SNM, therapeutic options for refractory 
OAB symptoms were limited to invasive and irreversible surgical procedures, such 
as ileocystoplasty or urinary deviation procedures with considerable complication 
rates. Patients with urinary retention are dependent on self-catheterization, which 
forms a daily inconvenience.  
The results of his thesis show that SNM can give lasting improvement in patients 
with symptoms of OAB and non-obstructive urinary retention (Chapter 2 and 
Chapter 3). 
But there still is a considerable group of implanted patients that do not benefit 
optimally from SNM.  
Optimizing selection of patients who have the greatest likelihood of having benefit 
from an SNM system remains a challenge.  
A study has been performed on predictive factors for succes of the PNE test. 
Scheepens et al studied predictive factors of having a positive PNE and found the 
following positive predictors: having had a intravertebral disk repair, urinary 
complaints over 7 months before undergoing PNE, and having OAB wet. A negative 
predictor was having neurogenic bladder dysfunction.2 
Several studies have been carried out into predictors of the results of definitive 
SNM implants. 
The predictive value of the age at which SNM implant takes place remains an issue 
of debate, as there are contradictory study results. 
Amundsen et al found that having an age older than 55 and comorbidity of more 
than three chronic diseases were associated with lower success rates of SNM in 
urgency symptoms.3 However, in another study in 19 elderly females with OAB pa-
tients in 2009, the success rates and complication rates that were found were as 
described in this thesis, but device removal rates were increased.4  
In conclusion, there are no unambiguous data yet that allow for a preselection of 
candidates for SNM. Therefore the temporary test procedure is the only currently 
known method to predict outcome of the definitive SNM implant and to select 
appropiate candidates.  
 
The usual method of determining whether a patient is a responder to SNM is the 
PNE test.  
The average success rate of the PNE lies around 50%.5,6 In Chapter 4 our first ex-
periences with temporary testing with the Tined Lead are described. This new lead 
has as advantages that it  can be implanted in a day care surgery setting and test 
lead migration occurs less often due to fixation of the lead with silicone barbs in the 
fascia. This allows for longer testing, compared to the PNE. The maximal duration of 
the conventional PNE is up to a week and with the Tined lead an average testing 
period was 12 days, with an outlier of 31 days without complications. 
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The overall success rate of testing through the Tined Lead of 70% to 80% in this the-
sis, is confirmed by other authors.7,8,9 Therefore testing through the Tined Lead 
seems to be superior over the conventional PNE when considering the increase of 
the chance of a positive test. Furthermore, the electrode configuration leading to a 
positive outcome during the test can be carried over after definitive implant, as the 
testing lead is used as a definitive lead. However, comparison of long term results of 
definite implants after a positive PNE versus a positive Tined Lead test does not 
show a significant difference in ultimate outcome.9  
Despite the increase of likelihood of a positive result after Tined Lead testing 
compared to the PNE, the PNE still retains its value as a test method.  
The costs of the conventional PNE are considerably lower than the costs of the 
Tined Lead prodecure. It can be carried out in an outpatient setting and is therefore 
more easily accessible. Testing with the Tined Lead requires an operating room and 
fluoroscopy.  The PNE also allows for an easily accessible manner to determine 
whether patients can handle the stimulation equipment and are willing and able to 
follow the instructions and to maintain adequate voiding diaries.  
 
In our single center study in Chapter 3, we have concluded that technical improve-
ments led to decrease of complication rates. The stimulation equipment has im-
proved, as the implantable pulse generator (IPG) became more advanced.  
The Itrell-I model used a strong magnet to allow the patient to switch the stimulator 
off, while later models were supplied with a Patient Programmer that works 
through telemetry. In addition to switching the stimulator on and off, it also allows 
for changing stimulation amplitude. In the first version of the IPG, changing stimula-
tion settings could only be done in a surgical procedure.  
In 2006, the latest Interstim-II IPG, model 3058 became available. Its volume of 14 
cm3 is considerably reduced, compared to its predecessor, the InterStim-II model 
3023 with a volume of 22 cm3. Solid long term results of the new IPG are not 
available, but it is expected that the rate of pain complaints at the IPG site will 
decrease, especially in physically active patients.  
During the development of SNM, implant techniques improved as well. Classically, 
the SNM system was implanted through an open surgical procedure, with direct 
placement of the lead and suturing it to the sacral periost. The IPG was placed in 
the left or right lower abdominal quadrant. The buttock placement, ie. placing the 
IPG about 5 cm caudally to the iliac crest, gave less pain at the IPG site at follow-
up.10 Operation time decreased from 2.5 hour to 1-1.5 hour as patients required no 
more turns on the operating table during surgery.  
Currently, the open procedure has been replaced in virtually each centre by mini-
mal invasive implant with the Tined Lead. Placement occurs under local anesthesia, 
therefore both sensory and motor responses can be used to determine optimal lead 
placement.  
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The literature seems to be in agreement that a motor response is required, at least 
during testing, to achieve efficacy of stimulation.8,11 But it is not clear what the sig-
nificance of a sensory response is for achieving improvement of voiding symptoms.  
Both during the test phase and after definitive implant, the stimulation amplitude 
can be regulated by the patient to such a voltage that patients feel the stimulation, 
but not in an unpleasant manner. However in our clinical experience, there are 
patients that have benefit of SNM without feeling the stimulation. The exact role of 
the patient’s sensory perception during test procedures and during stimulation by a 
definitive implant is still under debate.  
In the follow-up visits after SNM implant, sensation plays a role in troubleshooting. 
In most reprogramming sessions the sensory response of the patient is the only 
guide for choosing new stimulation settings.  
In the clinical practice is a distinction between patients with good results of SNM 
with or without feeling the stimulation. For patients with SNM for faecal complaints 
Koch et al. have found that patients can have positive results when stimulated be-
low sensory threshold.12  
Peters et al investigated the relation between a sensory response during lead im-
plant and the outcome of SNM after 24 months.13 They found no significant differ-
ence in outcomes between patients with and patients without a sensory response 
during implant. About 32% of the patients included in the study were implanted for 
interstitial cystitis. Care must be taken to extrapolate this results to the SNM 
population as the proportion of interstitial cystitis patients in the study is large, 
compared to the general SNM population.  
The research of the working mechanism of SNM seems to point to changes in cere-
bral structures that process afferent information from the bladder.14,15 It would be 
interesting to research the role of patient’s sensation on the efficacy of chronic 
SNM in long term studies with sufficient study subjects. 
 
Migration rates of the Tined lead, used as definitive lead, were found to be 2.1% in 
one long term study with 200 implanted patients and in another study with 64 pa-
tients the migration rate was 1.6%.16,17 
This figure is lower than the proportion of suspected lead migration of 3.3% found 
in the long term study with the conventional lead in Chapter 2. 
When placing the lead at the correct depth, the tines are placed in the 
subcutaneous tissue. It is assumed that fixation of the tines takes place due to 
fibrosis. In the short term, for example in the case of a failed first stage procedure, 
the lead can easily be removed by applying moderately firm traction perpendicular 
to the sacrum. In a situation after a definitive implant, forces as such will not occur. 
Furthermore, after both classical method and after minimal invasive implant, 
patients are advised to avoid bending and sudden movements of their backs for six 
weeks. In both studies describing lead migration, change of physical activity or 
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change in body weight are not mentioned in patients with lead migration. As the 
tines of the Tined Lead fixate in the subcutaneous tissue, changes in properties of 
this tissue or the surrounding musculature might predispose to lead migration. 
When this hypothesis is confirmed in further studies, patients can be counselled 
regarding lifestyle changes and the chance of lead migration.  
 
The initial stimulation parameters that are used are as follows: continuous stimula-
tion with a frequency of 10 Hz and a pulse width of 210 μsec. 
These parameters have been arbitrarily chosen and until now little research has 
been performed on efficacy of different parameter settings. Marcelissen et al have 
evaluated four different pulse rates in fifty patients with suboptimal effect. 
Eighteen out of 22 patients with stimulation related pain with stimulation at 10 Hz 
had pain relief when stimulated with another frequency. In several younger pa-
tients, stimulation at 40 Hz led to significant improvement in voiding parameters.18 
The results by Marcelissen et al show that an algorithm for tailoring the pulse rate 
settings in individual patients may improve outcomes and decrease adverse events, 
such as stimulation related pain. Until now, there are no studies into the effect of 
changes in pulse width or frequency on outcomes of SNM.  
 
Most patients are advised to leave their stimulation system on for 24 hours per day 
and to switch it of when driving or when working with heavy machinery. This advise 
is given to prevent accidents by sudden increase of stimulation sensation due to 
swaying of the end of the electrode towards the nerve.  
In our clinical experience there are patients who keep their favourable results after 
switching their IPG of or after temporary testing.   
In Chapter 5 we have investigated the feasibility of neuromodulation on demand. 
We found that 10 out of 16 patients were able to have their system switched off for 
at least on average 12.4 hour per day without worsening of symptoms. It is not 
clear why there were patients who were able to interrupt their stimulation without 
recurrence of symptoms and who were not able to do so.  
A few patients felt comfortable with manually controlling their SNM system. We 
expected that patients would find controlling the stimulation bothersome. An 
explanation might be that patients whose daily lives were first centered around 
their urinary symptoms become symptom free, but depend on their stimulation 
system to achieve symptom resolution. Giving the patients more control over their 
SNM system might improve their feeling of self-efficacy. Research into long term 
efficacy in on demand SNM is desirable, but interesting as well would be to assess 
differences in quality of life between patients with continuous SNM versus on 
demand SNM. Furthermore, on demand SNM may increase battery life of the IPG 
and delay the necessity for surgical IPG replacement. 
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One of the hypotheses in the on demand SNM study was that interruption of 
stimulation would prevent adaptation of the nerve system to the stimulation. In the 
literature little is known about the effects of prolonged continuous stimulation on 
peripheral nerves and on cerebral structures.  
Once patients achieve good results with the test procedure and have a definitive 
implant, globally 70% keep their good results at a follow-up of up to five years. This 
means that 30% lose their initially favorable results. This group of patients form a 
challenge for the team involved in SNM.  
First step of troubleshooting is ruling out technical failures as a cause of non-
responding.  
Lead migration can be diagnosed with plain radiography. The IPG can measure the 
impedance in the stimulation circuit. A low impedance ( < 400 Ω) is indicative for a 
short circuit. This may happen in case of a damaged lead. Should the impedance be 
too high ( > 1500 Ω), then a lead breakage or a loose connection may be the case.  
In most of the 30% of the patients with loss of efficacy, however, technical 
problems are ruled out.  
McLennan measured compound muscle action potentials (CMAPs) at the anal 
sphincter in 10 female patients to determine the optimal course of action.19 The 
CMAPs were measured for each electrode configuration. The electrode 
configuration with the CMAP with the highest amplitude was deemed optimal. If a 
patient with loss of efficacy had an optimal configuration, then reprogramming was 
deemed useless. This was the case in 2 patients. If the configuration was not 
optimal, then the optimal settings were chosen in 5 patients. If no response was 
found, a lead migration was suspected.  
All patients in this study had their loss of efficacy after a relatively short period after 
implant. The mean period before loss of SNM efficacy was 5.3 months. Therefore it 
would be interesting to determine whether this method of troubleshooting would 
also be valid for patients with loss of efficacy after a longer period of SNM.  
Ghazwani et al found in their patient series of 143 patients 9 patients with loss of 
efficacy.20 These patients had required higher amplitudes (4 ± 1.2 V vs. 2.83 ± 0.7 V) 
during the PNE procedure. The amplitude at implant and the current amplitude 
ware increased as well.  
Impedances at the time of loss of efficacy were also higher in the non-responders:  
(1032.4 ± 181 Ω vs. 590 ± 44.6 Ω). The most obvious explanation may be that the 
amplitude requirement and impedance is increased due to fibrosis between the 
lead and the nerve, but that does not explain the higher amplitudes during the 
acute PNE. It would be interesting to see whether this association is also seen in 
other SNM centers.  
 
These two studies investigated the peripheral nerves, but there is no data on cere-
bral mechanisms in non responders available. It is clear that in patients with SNM 
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cerebral mechanisms are also involved.14,21,22 A PET-CT or fMRI study comparing 
cerebral perfusion areas in patients with loss of efficacy versus effect maintainers 
might be of interest.  
 
In clinical experience with patients with lower urinary tract symptoms, a proportion 
of patients have psychological complaints or a psychiatric history. In the literature 
there are indications for a relation between a psychiatric history and an increased 
chance of loss of efficacy. Weil et al found that in patients with a psychiatric history, 
the effect of SNM lasted with a median of 12 months and in the remaining patients 
without a psychiatric history the effect lasted over 36 months.23 Furthermore the 
number of re-operations was higher in patients with a psychiatric history.  
Marcelissen et al prospectively investigated the correlation between questionnaires 
into psychological factors and the results of the PNE and definitive implant.24 No 
relation between the score on the questionnaires and the outcome has been found. 
But there was a significant relation between a psychiatric history and the number of 
adverse events. Patients with a psychiatric history had 75% chance of an adverse 
event, while non-psychiatric patients had 13% chance of an adverse event. 
However, the duration of the follow-up was not mentioned in the article.  
In 2009 White et al could not find a significant correlation between a psychiatric 
history and increased rate of adverse events in 221 patients with SNM, but did find 
an increased rate of SNM implant removal in patients with a psychiatric history.25  
In conclusion, there seems to be a relation between having a psychiatric history and 
the occurrence of adverse events and SNM explant rates. It would be useful to 
further investigate the cause of the increase in adverse events in this group of 
patients. This may lead to better pre-implant patient counselling or the discovery of 
risk factors that may be modifiable.   
 
Chapter 6 describes the study into sexual function of female patients with SNM. In 
our clinic, several female patients mentioned that their sexual functioning improved 
after SNM. The study was devised to verify the hypothesis that SNM does improve 
sexual function in patients with lower urinary tract or faecal symptoms. 
The second objective was to determine whether the improvement was due to a 
physiological reaction on SNM of because of an improved well-being. Due to a low 
number of study subjects, no significant results have been found. Although the  
phletysmography results and the trend towards improvement of the Mah Orgasm 
Score may indicate a physiological reaction on SNM.  
Reasons for the non-significant results are the low number of included patients and 
by the fact that our included patients probably experienced minimal problems with 
sexual functioning. This is a consequence of the inclusion criteria in the study; pa-
tients had to be sexually active to be able to fill in the questionnaires correctly.  
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Pauls et al did find improvement in sexual function after SNM implant, but could 
not differentiate between the mechanism of improvement either.26 
In their study an inclusion criteria was that patients had to be sexually active as 
well.  
To have a better understanding, it would be useful to perform a study into 
improvement with SNM in patients who have known sexual dysfunction.  
FUTURE PERSPECTIVES 
From its introduction about twenty years ago up to now, SNM has seen a quick ac-
ceptance and remarkable growth. It has found its place between first pharmacol-
ogical treatment and invasive surgical procedures for patients with refractory, in-
validating symptom complexes.  
The challenge for the future lies in optimizing SNM therapy to decrease the rate of 
patients who lose efficacy of their implant. One method of achieving this is 
optimization of patient selection.  
While testing with the Tined Lead increases the chance of a successful test 
procedure, it does not seem to have an impact on post implant loss of efficacy. A 
partial solution may lie in the selection of patients who undergo the temporary test. 
Further research has to be carried out regarding additional pretest screening 
instruments.  
It would also be interesting to determine whether psychological counselling before 
or during definitive SNM implant would be useful. This counselling may consist of 
the management of patient’s expectations towards SNM results.  
Several studies into optimization stimulation parameters, for example the on de-
mand study in this thesis and the study into rate changes by Marcelissen et al., 
show that subgroups of the research population might benefit from other SNM pa-
rameters than the usual parameters.20  
A proposed hypothesis for this phenomenon is that the causes of LUTS are 
multifactorial and factors might have a different expression in individual patients. In 
addition, causative factors can react differently on SNM. This may account for the 
differences in response in SNM and for differences in reaction on changes in 
stimulation parameters.  
Therefore, besides more research into the causes on LUTS and working mechanism 
of SNM, research into an algorithm for customizing parameters as pulse rate, pulse 
width or continuous stimulation versus on demand stimulation in individual 
patients may yield better long term outcomes.   
 
The indications of SNM are expanding. In addition to idiopathic OAB and non-
obstructive urinary retention SNM is also successfully used in faecal incontinence or 
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constipation, interstitial cystitis and pelvic pain syndromes and in patients with neu-
rogenic voiding complaints.27,28,29  
SNM is successfully used in patients with incomplete spinal injury.30 Recently Sievert 
et al published a study on bilateral SNM in 10 patients with complete spinal cord 
injury during the spinal shock phase.31 After a mean follow-up of 26 months, there 
was a decrease of urinary incontinence and urinary tract infections, compared to 6 
control patients. Average catheterized volume in the intervention group was 582ml 
per catheterization (480 – 650 ml) versus 208 ml; (57–314 ml) in the control group. 
Patients were also not dependent on laxatives for defacation.  
Usually, defaecation needs to be pharmacologically regulated and unpredictable 
bowel movement is a very troublesome consequence after spinal cord injury. Two 
male patients were able to achieve penile erection with specialized SNM settings. 
 
These results seem promising and may have considerable impact on bladder and 
bowel management in spinal cord injury.  
Another study in patients with spinal cord injury by Horvath et al in 2011 re-
searched the feasibility of conditional pudendal neuromodulation.32 In 9 patients  at 
least a year after initial complete or incomplete spinal cord injury,, a closed-loop 
system was used to record detrusor pressure during artificial bladder filling and to 
apply electrical stimulation of the pudendal nerve when the detrusor pressure rose 
above 40 cmH2O. In 8 patients the average cystometric capacity increased, 
compared to no stimulation and in 6 patients there was a non-significant increase 
compared to continuous stimulation.  
This study shows that conditional neuromodulation is feasible, at least in a 
laboratory situation. Further refinement and a different method of acquiring 
detrusor pressure changes might make a closed-loop system for conditional 
neuromodulation a feasible and useful therapy option in patients with lower urinary 
tract symptoms.   
More research in responding and non-responding in patients with SNM for 
neurogenic LUTS might give more insight in the working mechanism of SNM.  
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Chapter 1 starts with a brief description of the burden that LUTS give on the pa-
tients and on society. Symptoms of dysfunctional voiding are rather common and 
have a significant impact on quality of life in patients and have considerable eco-
nomical consequences in society. Chapter 1 also contains an overview on the his-
tory and the procedure of Sacral neuromodulation (SNM). SNM is a treatment of 
voiding symptoms by stimulating the nerve root that runs through the third fora-
men of the sacral bone. The exact working mechanism is still not known, but chap-
ter 1 provides an overview of the existing knowledge and current research on this 
subject.  
Furthermore, the aims of this thesis are outlined.  
 
Chapter 2 gives an overview on the neurophysiology of normal voiding. Storage and 
disposal of urine are controlled by several reflex arcs in cerebro and in the spinal 
cord, controlling a finely tuned coordination between bladder and sphincter com-
plex. The pathophysiology of overactive bladder symptoms and of nonobstructive 
urinary retention that can be eligible for treatment by SNM is discussed. In addition, 
a few more recent indications for SNM are described.  
 
Chapter 3 presents the results of a prospective multicenter study on the effect of 
SNM with a follow-up period of 5 years. Clinical success of SNM is arbitrarily defined 
as at least 50% improvement in relevant voiding parameters, measured with void-
ing diaries. Clinical success is used as a criterion for a succesful test procedure, 
while in this study it is used as an end point to describe stimulation efficacy. The 
clinical success rate after 5 year follow-up is 68% for patients with urgency inconti-
nence, 56% in patients with urgency-frequency and 71% in patients with retention. 
Furthermore, the rate of adverse events and reoperation rate are reported. There 
were no life threatening or irreversible events and 67% of the implanted patients 
had at least one adverse event. 39,5% of the patients needed surgical correction of 
an adverse event, including the need for stimulator replacement because of battery 
depletion.  
 
Chapter 4 describes the results of a retrospective study on long term outcome at 
the Department of Urology in the Academisch Ziekenhuis in Maastricht. 
This study included 149 patients, 107 had overactive bladder symptoms and 42 had 
urinary retention. Mean follow-up was 64.2 (sd= 38.5) months. In the whole group 
194 adverse events occurred. 6 Patients had an infection in their implanted system, 
but no patient was explanted for infection. Most events could be solved by giving 
advice or by reprogramming the stimulator. 129 Re-operations have been 
performed and 21 patients had their system explanted.  
A difference in in the incidence of re-operations was found between the groups of 
patients implanted before or after 1996. However, this did not reflect on the 
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subjective results, these stayed equal between those groups. Reasons given for the 
difference in re-operation rates were: a learning curve in initial SNM therapy and 
technical and procedural improvements.  
 
Chapter 5 shows initial results and median term follow-up with a new lead that can 
be implanted in a minimally invasive procedure under local anesthesia. This allows 
for temporary testing where, in the case of a positive result, the lead can function 
as a definitive lead. 49 patients, 39 with refractory overactive bladder symptoms, 10 
with urinary retention, were implanted with the tined lead under local anesthesia. 
The average test period was 12.4 days, (sd 5.8 days). Patients were implanted with 
an implantable pulse generator when they had at least 50% improvement in voiding 
diaries. Average follow-up for implanted patients was 15.5 months (sd= 7.9 
months). Results: 10 patients had a single stage implant, 39 had a two-stage im-
plant. Of 39 patients with 2-stage implant 31 (79.5%) were positive, 8 (20.5%) were 
not. 31 patients were included in follow-up. At last follow-up 28 (90.3%) patients 
had more than 50% improvement in diary parameters and 3 (9.7%) had not. Seven 
patients had an adverse event. One incomplete electrode migration was seen and 
was treated conservatively. The Tined Lead seems to give a higher chance of a posi-
tive test result than the conventional PNE and gives good median term results.  
 
Chapter 6 investigates the feasibility of intermittent SNM. The general opinion is 
that patients need to be stimulated continuously to achieve their results.  
However, there is anecdotal evidence that stimulation can be interrupted without 
losing efficacy on voiding symptoms. Intermittent stimulation could have as 
advantage that it might save battery life, and perhaps postpone loss of efficacy in 
the long term.  
21 Patients were randomized in two groups; 16 patients in the on demand group 
and 5 patients were controls, in addition to a run in period of two weeks where 
each patient performed his or her own control. In the on demand stimulation 10 
out of 16 patients seemed to be able to switch the stimulator off for on average 
12.4 hours without increase of voiding symptoms. An unexpected beneficial side 
effect was that several patients felt more comfortable with on demand stimulation 
as it gives them a feeling of control over their voiding symptoms.  
 
Chapter 7 shows the results of a study on the influence of SNM on sexual function 
in female patients, treated for urinary symptoms or faecal incontinence.  
Eight patients were analyzed with an array of sexological questionnaires into sexual 
function and dysfunction and three of these eight patients underwent measure-
ment of the vaginal pulse amplitude with vaginal phletysmography.  
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Although no statistically significant results were found, the combination of the phle-
tysmography results and a trend towards improvement of orgasm perception after 
SNM implant suggest a physiologically mediated improvement.  
Inclusion of subjects was very slow, this may be because for inclusion current sexual 
activity was a criterion, in order to fill out the questionnaires, while sexual function 
may be deteriorated because of the voiding symptoms or faecal symptoms.  
 
Chapter 9 concludes this thesis with a discussion on the implications of the found 
results. SNM has proven to be a save and effective therapy, but its results depend 
on careful selection of potential candidates. Until now, the only means of selecting 
those who will respond favourably on definitive SNM remains a temporary trail pro-
cedure.  
Testing with the new minimal invasive electrode increases the rate of positive 
temporary test results, but it is not clear whether it will give better SNM results in 
the long term. Other means of optimizing long term results might be on demand 
stimulation and tailoring stimulation parameters towards the individual patient. 
The indications for SNM are expanding and SNM might have a place in patients with 
neurogenic LUTS. Further research might be directed into further refinement of 
SNM technology and into additional selection criteria.  
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Nederlandse samenvatting  
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Dit proefschrift gaat over de behandeling van chronische, veelal onbegrepen, 
klachten van het plassen met sacrale neuromodulatie. Sacrale neuromodulatie is 
een behandeling waarbij men de zenuw die door het derde foramen van het 
heiligbeen (het sacrum) loopt, stimuleert met elektrische pulsen. Deze techniek is in 
de 80-er jaren van het vorige decennium ontwikkeld door een groep onderzoekers 
in San Fransico.  
Een neuromodulatiesysteem bestaat uit een in het heiligbeen geplaatste electrode. 
De elektrode is verbonden aan een onderhuids in de bil geïmplanteerde stimulator.  
De exacte werking van sacrale neuromodulatie is vooralsnog niet bekend. Wel is 
bekend dat de werking niet wordt veroorzaakt door directe stimulatie van blaas of 
urinewegen, maar dat de stimulatie veranderingen teweeg brengt in de voor het 
plassen verantwoordelijke reflexbogen in het ruggenmerg. Verder zijn er aanwijzin-
gen dat neuromodulatie ook veranderingen geeft in activiteit van de hersen-
structuren waarin het plassen geregeld wordt. 
De plasklachten kunnen bestaan uit urgencyincontinentie, ook wel aandrangs-
incontinentie genoemd, urgency-frequency (het vaak en met grote aandrang kleine 
beetjes plassen) en het vasthouden van urine (retentie) zonder obstructie beneden 
de blaas.  
De patiënten met chronische blaasklachten die in aanmerking komen voor sacrale 
neuromodulatie vormen een lastig te behandelen groep. Het hebben van deze 
langdurige klachten is sociaal invaliderend doordat patiënten afhankelijk zijn van 
incontinentiemateriaal of hun activiteiten moeten plannen op basis van het in de 
buurt zijn van een toilet. Patiënten met retentie zijn afhankelijk van zelfcathete-
risatie, wat een aanzienlijk dagelijks ongemak geeft. In beide gevallen zijn ook de 
kosten die de aandoening met zich meebrengt, aanzienlijk.  
In het geval van aandrangsklachten wordt er gestart met adviezen ten aanzien van 
vochtinname, eventueel aangevuld met bekkenbodemfysiotherapie. Bij onvoldoen-
de effect worden blaasremmende medicamenten gegeven. Het nadeel hiervan is 
dat deze systemisch werken en daardoor in veel patiënten hinderlijke bijwerkingen 
geven, waardoor het percentage patiënten dat na enige tijd met de medicatie stopt 
hoog is.  
Voor de introductie van de sacrale neuromodulatie was de laatste optie operatieve 
behandelingmet blaascapaciteitvergrotende technieken of blaasvervangingen. Deze 
operaties zijn onomkeerbaar en kennen een aanzienlijk complicatiepercentage.  
Sinds de introductie van de neuromodulatie in de jaren 90, heeft deze therapie zijn 
plaats gevonden in de rij mogelijkheden voor de patiënten met plasklachten. De 
techniek kent goede resultaten en is veilig en omkeerbaar.  
De procedure voor neuromodulatie is als volgt.  
Als een patiënt kandidaat voor neuromodulatie lijkt te zijn, vindt eerst een test-
procedure, de Perpiheral Nerve Evaluation (PNE), plaats. Een tijdelijke elektrode, 
verbonden aan een uitwendige stimulator, wordt geplaatst. Na ongeveer een week 
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worden door de patiënt bijgehouden plasdagboekjes van voor de stimulatie 
vergeleken met tijdens de stimulatie. Bij 50% of meer verbetering van de 
parameters in de plasdagboekjes wordt in overleg met patiënt besloten voor 
implantatie van een definitief systeem.  
In de beginperiode werd deze implantatie gedaan in een operatie onder algehele 
anesthesie. Implantatie van de elektrode gebeurde met een incisie over het sacrum, 
waarna de elektrode geplaatst werd en verankerd aan het bot.  
Sinds 2004 wordt gebruik gemaakt van een minimaal invasieve elektrode plaatsing 
die kan plaatsvinden onder lokale verdoving. Hierdoor kan de elektrode die 
definitief geplaatst kan worden ook gebruikt worden als testelektrode.  
 
Het doel van dit proefschrift is het in kaart brengen van de lange termijnresultaten 
en de complicaties van sacrale neuromodulatie. Verder worden de eerste 
testresultaten op de afdeling Urologie van het Academisch Ziekenhuis in Maastricht 
met de minimaal invasieve elektrode beschreven. Er wordt een onderzoek 
beschreven naar toepasbaarheid van onderbroken stimulatie in plaats van de 
gebruikelijke continue stimulatie. Voordelen hiervan kunnen zijn dat de batterij van 
de stimulator langer meegaat, zodat het operatief wisselen van de stimulator 
uitgesteld kan worden. Verder blijkt dat op langere termijn een aanzienlijk 
percentage patienten geen effect van de stimulatie meer heeft, terwijl er wel 
adequaat gestimuleerd wordt. Mogelijk komt dit door aanpassingen in het 
zenuwstelsel aan de langdurige stimulatie. Als dit het geval is, zou onderbroken 
stimulatie ervoor kunnen zorgen dat dit effect uitgesteld wordt.  
Bij de controlebezoeken aan de poli door patiëntes met een geïmplanteerd neuro-
modulatie systeem werd door enkele vrouwelijke patiënten spontaan verbetering 
van het sexuele functioneren gemeld. In dit proefschrift is een studie gedaan met 
als doel om na te gaan of er inderdaad verbetering van sexueel functioneren is bij 
vrouwelijke patienten met neuromodulatie en of deze eventuele verbetering 
veroorzaakt wordt door effecten van stimulatie van de zenuw die onder andere 
naar de geslachtsorganen loopt of door een verbeterd welbevinden doordat de 
plassymptomen zijn opgelost.  
 
Hoofdstuk 1 bevat een introductie voor dit proefschrift. Het vóórkomen en de 
gevolgen van blaasklachten wordt beschreven. Verder wordt een overzicht gegeven 
van het tot nu bekende onderzoek naar de werking van neuromodulatie. Hoofdstuk 
1 bevat ook een korte beschrijving van de historie en de procedure van sacrale 
neuromodulatie.  
 
Hoofdstuk 2 beschrijft de neurofysiologie van het normale plassen. De controle van 
opslag en evacuatie van urine wordt geregeld door een goed gecoördineerd 
netwerk van reflexen in ruggenmerg en brein. Ook wordt de pathofysiologie van de 
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belangrijkste indicaties voor sacrale neuromodulatie, te weten symptomen van een 
overactieve blaas en urineretentie, besproken. Ook worden enkele recentere 
indicaties besproken.  
 
Hoofdstuk 2 beschrijft de resultaten van een grootschalig prospectief multicenter 
onderzoek naar de lange termijnresultaten van sacrale neuromodulatie. 152 
Patienten met urgency incontinentie, urgency/frequency of urineretentie die waren 
geïmplanteerd met een neuromodulatiesysteem werden voor vijf jaar jaarlijks 
gevolgd met behulp van analyse van plasdagboekjes. Verder werden de compli-
caties en heroperaties bijgehouden. De stimulatie werd als succesvol gezien 
wanneer er 50% verbetering was in dagboekparameters bij het laatste bezoek, 
vergeleken met de parameters voor implantatie. Succesvolle stimulatie na 5 jaar 
werd bij 68% van de patiënten met urgency incontinentie, 56% van de patiënten 
with urgency-frequency en in 71% van de patiënten met retentie vastgesteld. Er 
hadden zich tijdens de 5 jaar follow-up geen levensbedreigende of onomkeerbare 
complicaties voorgedaan. 76% van de patienten had minstens één complicatie; 39,5 
% van de patiënten moesten geheropereerd worden in verband met een 
complicatie. In deze 39,5% zitten ook patiënten bij wie de stimulator moest worden 
vervangen omdat de batterij leeg was. 
Er werd een sterke relatie gezien tussen het resultaat na 1 jaar en na 5 jaar, bij een 
positief resultaat na 1 jaar is de kans groot dat het resultaat na 5 jaar ook positief is.  
 
Hoofdstuk 3 bevat een overzicht van de lange termijnresultaten van sacrale 
neuromodulatie op de afdeling Urologie in het Academisch Ziekenhuis in Maas-
tricht.  
Deze resultaten werden verkregen door statusonderzoek. De statussen van 149 
patiënten werden nagezocht op resultaten en complicaties. Overactieve 
blaassymptomen waren de indicatie voor neuromodulatie in 107 patiënten; 
retentie in 42 patiënten. De gemiddelde follow-up bedroeg 64,2 (sd = 38,5) 
maanden. In de gehele groep werden 194 complicaties geregistreerd. Bij 6 
patiënten werd een infectie rond het systeem gevonden, maar dit was bij geen van 
de patiënten reden tot verwijdering van het systeem. De meeste complicaties 
konden worden opgelost door adviezen te geven of het systeem te 
herprogrammeren. 129 heroperaties werden uitgevoerd en in 21 patiënten werd 
het systeem uiteindelijk verwijderd. Er was een opmerkelijk verschil tussen de 
aantallen heroperaties in patiënten die geïmplanteerd werden voor 1996 en in 1996 
of later. Dit verschil werd niet teruggezien in de effectiviteit van neuromodulatie bij 
patiënten die voor of na 1996 werden geïmplanteerd. Hieruit werd geconcludeerd 
dat het aantal complicaties daalde door een leercurve en door verbeterde 
elektroden, stimulatoren en operatietechnieken.  
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Hoofdstuk 4 is een onderzoek naar de eerste ervaringen van de afdeling Urologie in 
het Academisch Ziekenhuis in Maastricht met een nieuwe elektrode die in een 
minimaal invasieve procedure geplaatst kan worden onder lokale verdoving.  
Hierdoor is de elektrode bruikbaar als tijdelijke testelektrode en bij goede 
testresultaten kan aan dezelfde elektrode een implanteerbare pulsgenerator 
gekoppeld worden. Doordat de kans op verschuiven van de elektrode kleiner is dan 
bij de PNE, kan er langer getest worden dan bij de standaard tijdelijke test-
elektrode. Er werden 49 patiënten met deze elektrode geïmplanteerd; 39 patiënten 
met overactieve blaassymptomen en 10 patiënten met retentie. De gemiddelde 
testperiode bedroeg 12,4 dagen (sd = 5,8 dagen) Patiënten werden met een 
neurostimulator geïmplanteerd bij 50% of meer verbetering in plasdagboekjes en 
gevolgd voor gemiddeld 15,5 maanden (sd = 7,9 maanden).  
Bij 10 patiënten met een positieve standaard test werd de elektrode als definitieve 
elektrode geïmplanteerd. Bij de 39 andere patiënten hadden 31 patiënten (79,5%) 
een positieve test en 8 (20,5%) niet. Het percentage patiënten met een positieve 
test is hoger dan de 50% die bij de PNE wordt gezien. Verder hield 90,3% van de 39 
op de middellange termijn gevolgde patiënten hun positieve resultaat.  
Bij 7 patiënten werd een complicatie gezien en bij 1 patiënt werd een verschuiving 
van de elektrode gezien, maar deze patiënt kon worden behandeld door 
herprogrammeren van de stimulator. De Tined Lead geeft een hogere kans op een 
positieve test voor sacrale neuromodulatie en de resultaten op middellange termijn 
zijn goed.  
 
Hoofdstuk 5 laat de haalbaarheid van onderbroken neuromodulatie zien. De 
algehele opinie was dat patiënten 24 uur per dag continu gestimuleerd moeten 
worden om hun resultaten te houden. Wel wordt geadviseerd om de stimulator uit 
te zetten bij auto rijden of het bedienen van zware machines. Hiermee hoopt men 
ongelukken te voorkomen doordat de stimulatie ineens heftiger wordt bij 
onverwachte bewegingen. Dit leidt in de praktijk niet tot toename van plasklachten.  
Voordelen van onderbroken stimulatie kunnen zijn dat er zuiniger wordt omgegaan 
met de batterij van de stimulator, waardoor het operatief wisselen van de 
stimulator kan worden uitgesteld. Ook is er een aanzienlijk aantal patiënten waarbij 
na langere tijdsduur van sacrale neuromodulatie de plasklachten terugkomen, 
ondanks technisch adequate stimulatie. Een theorie die dit zou kunnen verklaren is 
dat het zenuwstelsel zich aanpast aan de stimulatie. Onderbroken stimulatie zou dit 
proces kunnen vertragen of misschien kunnen stoppen.  
Zestien patiënten met twee weken continue en twee weken onderbroken 
stimulatie werden vergeleken met 5 controle patiënten en met zichzelf. De 
patiënten met onderbroken stimulatie werd gevraagd om de simulator uit te zetten 
en in te schakelen als zij weer klachten kregen. Verder hielden zij bij hoe lang de 
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stimulator in- of uitgeschakeld was en werden in beide groepen plasdagboekjes 
bijgehouden. 
In de onderbroken stimulatiegroep konden 10 van de 16 patiënten hun stimulator 
gemiddeld 12,4 uur per dag uit houden zonder noemenswaardige toename van 
klachten en verslechtering van de waarden in de plasdagboekjes.  
Een effect dat wij niet hadden verwacht was dat enkele patiënten het prettig 
vonden om zelf controle te houden over wanneer het systeem aan of uit staat.  
 
Hoofdstuk 6 beschrijft een onderzoek naar de invloed van sacrale neuromodulatie 
op het sexueel functioneren van vrouwelijke patiënten met klachten van een 
overactieve blaas, urineretentie of faecale incontinentie.  
Voor en na de implantatie van het neuromodulatiesysteem werd een batterij van 
seksuologische vragenlijsten ingevuld door 8 patiëntes. Bij 3 van deze patiëntes 
werd voor en na de implantatie de vaginale doorbloeding gemeten in seksueel 
opgewonden en in neutrale toestand. Er werden geen statistisch significante resul-
taten gevonden, maar de combinatie van toegenomen orgasmescores en vaginale 
doorbloeding na implantatie lijken te wijzen op een verbetering die wordt veroor-
zaakt door een effect van de neuromodulatie op de vrouwelijke geslachtsorganen.  
De studie kende een lange looptijd door moeizame rekrutering van proefpersonen. 
Oorzaak hiervoor is vermoedelijk het feit dat proefpersonen seksueel actief moeten 
zijn om de vragenlijsten goed te kunnen invullen, terwijl de blaasklachten of faecale 
klachten ertoe zouden kunnen leiden dat patiëntes niet seksueel actief meer zijn.  
 
Hoofdstuk 9 sluit dit proefschrift af met een discussie over de implicaties van de 
gevonden resultaten. Sacrale neuromodulatie is effectief op de lange termijn bij de 
meeste patienten die behandeld worden met neuromodulatie voor urgency 
incontinentie, urgency-frequenct of urineretentie. De therapie vormt een waarde-
volle aanvulling bij de behandeling van deze hardnekkige en invaliderend klachten. 
Sacrale neuromodulatie is omkeerbaar en is veilig. Er treden weliswaar complicaties 
op, maar de meeste kunnen behandeld worden met advies of het herprogram-
meren van het systeem. Tevens hebben technische ontwikkelingen van de 
elektrode, de implanteerbare pulsgenerator en verbeterde operatietechnieken 
zoals het implanteren van de pulsgenerator in de bil in plaats van in de onderbuik 
tot afname van complicaties geleid. Er blijft echter een aanzienlijke groep patiënten 
waarbij het effect van de neuromodulatie op langere termijn verloren gaat.   
De enige manier om te bepalen of een patiënt in aanmerking komt voor neuro-
modulatie is vooralsnog een test met een tijdelijke elektrode. Probleem hierbij is de 
kans op verschuiving van de elektrode. Bij testen met de Tined Lead elektrode is de 
kans op verschuiving lager en kan langer getest worden. De kans op een positieve 
tijdelijke test is groter bij testen met de Tined Lead elektrode. Verder kan deze 
elektrode als definitieve elektrode gebruikt worden en patienten die met deze 
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elektrode geïmplanteerd zijn, houden op de middellange termijn gelijkwaardige 
resultaten als met de conventionele elektrode. Aangezien testen met de 
conventionele elektrode logistiek gemakkelijker en laagdrempeliger is, is deze 
elektrode vooralsnog de eerste keus. Onderbroken neuromodulatie is een haalbare 
vorm van neuromodulatie, waarbij in een meerderheid van de patiënten geen 
toename van klachten gezien wordt. Verder vindt een groep patiënten het 
aangenaam om het gevoel van controle over de stimulatie te hebben. Mogelijk kan 
deze neuromodulatiemethode het eerder genoemde verlies van werkzaamheid van 
neuromodulatie tegengaan, maar meer onderzoek naar onderbroken neuro-
modulatie is nodig. Het zou interessant zijn om naar een algoritme voor de 
instellingen van sacrale neuromodulatie over te gaan, waarin in plaats van de 
standaardinstellingen, gekeken wordt naar instellingen op maat per patient.  
Mogelijk zou dit tot nog minder uitval op lagere termijn en ongunstige bij/effecten 
kunnen leiden.  
In de studie naar verbetering van seksueel functioneren van vrouwelijke patiënten 
die neuromodulatie hebben voor blaasklachten of faecale klachten is geen 
overtuigend bewijs gevonden dat neuromodulatie daadwerkelijk verbetering van 
seksueel functioneren geeft. Een reden hiervoor is het lage aantal proefpersonen. 
Wel lijkt er een direct effect te zijn op de vrouwelijke geslachtsorganen, maar 
verder onderzoek met meer proefpersonen is wenselijk. 
Recent wordt er meer onderzoek gedaan naar de toepassing van sacrale neuro-
modulatie bij patienten met neurogene blaasklachten. Verder onderzoek naar de 
resultaten bij deze groep zou ook meer informatie kunnen geven onder het 
werkingsmechanisme.  
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